Small molecule drug-oligonucleotide conjugate and its application
Through the covalent coupling of small molecule drugs and functional oligonucleotides, the small molecule drug-oligonucleotide conjugates formed solve the problems of poor water solubility and difficulty in delivery of existing drugs, and achieve synergy for inflammatory signaling pathways Regulation improves therapeutic effect and reduces side effects.
Patent Information
- Application Number
- CN202210703857.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-06-21
AI Technical Summary
Existing inflammatory regulatory drugs face poor water solubility, difficulty in delivering drugs and major side effects. A single strategy is difficult to effectively regulate the inflammatory response, resulting in poor efficacy.
The small molecule drug-oligonucleotide conjugates formed by covalent coupling through chemical linkers can synergize with inflammation-related signaling pathways to improve drug solubility and Delivery capability to achieve coordinated regulation of inflammatory response.
It improves the solubility of drugs and cell uptake efficiency, realizes coordinated regulation of inflammation-related signaling pathways, enhances treatment effect, reduces toxic side effects, and provides a better treatment plan.
Smart Images

Figure CN115282283B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a small molecule drug-oligonucleotide conjugate and application thereof. Background Art
[0002] In recent years, the study of the mechanism of inflammatory response and the relationship between inflammation and disease has exploded. Through a large number of studies, people have a deeper understanding of the mechanism of inflammatory response and how inflammation affects the occurrence and development of many diseases. Based on the research results obtained, it is currently believed that inflammation may be the main driving factor for many diseases such as psoriasis, Sjögren's syndrome, dry eyes, uveitis, keratitis, conjunctivitis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, heart disease, diabetes, cancer, asthma, inflammatory bowel disease, Alzheimer's disease, etc. In the common inflammatory response process, the histamine molecules released by ruptured or activated mast cells, circulating basophils and platelets, vascular cell adhesion factor 1 (VCAM-1), endothelial cell adhesion molecule-1 (E-selectin) and intercellular adhesion molecule-1 (ICAM-1) in the blood circulation will cause vasodilation, thereby greatly increasing vascular permeability (Cardiovasc Hematol Disord Drug Targets 2008, 8, 252-260). The increase in vascular permeability will lead to local edema, allowing phagocytes, complement system proteins, eicosanoids, kinins, cytokines, platelet-activating factors and other substances to enter the blood vessels (JAllergy Clin Immunol 2010, 125, S3-S23), promoting the occurrence and development of inflammation. Among them, cytokines such as tumor necrosis factor, interleukin, lymphokine, monokine, interferon, colony stimulating factor, and transforming growth factor produced by monocytes, T cells, platelets and endothelial cells are all involved in inflammation-related reactions. In addition, when components of the innate immune system, monocytes (including macrophages and dendritic cells) and neutrophils are activated, the inflammatory response will also be enhanced.
[0003] The innate immune system recognizes bacteria and other damage through the recognition of transmembrane Toll-like receptors (TLRs) with specific ligands. For example, lipopolysaccharide (LPS) stimulation of TLR4 on macrophages triggers the synthesis of inflammatory factors such as TNF-α and IL-1β, and stimulates the production of immunomodulatory cytokine IL-12, which is necessary for acquired immune responses. Once macrophages are activated by inflammatory factors, their lifespan will increase and they will produce a large number of proinflammatory cytokines, including TNF-α, IL-1, IL-6, IL-12 / IL-23, IL-18, and high mobility group box protein 1 (HMGB1). These cytokines will further amplify the inflammatory response and trigger the acquired immune response. Circulating cytokines interact with specific receptors on different types of cells and activate Janus kinase / signal transducer and transcription protein (JAK-STAT), nuclear factor kappa B (NF-κB), and transforming growth factor β (TGF-β) signaling pathways, leading to inflammatory responses such as cell adhesion, increased permeability, cell apoptosis, and increased reactive oxygen species.
[0004] The common characteristics of inflammation-related diseases are the activation of related signaling pathways and the overexpression of multiple inflammatory cytokines after the destruction of immune balance, which in turn stimulates a persistent inflammatory response and has a destructive effect on the body. Based on the understanding of the mechanism of disease-induced inflammatory response and the immune activation process, researchers are committed to developing different types of drugs to achieve inflammation regulation and ultimately cure the disease. Existing inflammation regulation drugs mainly include small molecule drugs with immunomodulatory functions, antibody drugs targeting cytokines and receptors involved in inflammatory responses, and gene drugs that regulate the expression of genes related to inflammatory signaling pathways. Commonly used small molecule drugs with immunomodulatory functions include calcineurin inhibitors, mTOR inhibitors, glucocorticoids, vitamin D analogs, etc. The above small molecule drugs can be mass-produced at a low cost, and some small molecule drugs can also be made into oral preparations. However, small molecule drugs generally face poor water solubility, low bioavailability, and usually have strong side effects, and are not suitable for long-term use. Antibody drugs are usually highly targeted, fast-acting, and have excellent immunomodulatory effects, but these drugs generally need to be injected, and the production and treatment costs are high. In addition, long-term systemic administration can easily lead to drug resistance and other adverse reactions, and has strong toxic side effects, such as reduced immunity, and susceptibility to infection and cancer.
[0005] Functional oligonucleotide molecules (siRNA, antisense oligonucleotides) that target inflammatory response-related genes and achieve immune regulation as a new type of drug have low immunogenicity, a wide range of targets, can target both intracellular and extracellular targets, are not prone to drug resistance, and can regulate upstream signal pathways, providing more possibilities for immune regulation and disease treatment. However, due to the large molecular weight and negative charge of nucleic acid drugs, it is difficult for individual nucleic acid drugs to cross the cell membrane barrier, and thus faces the problem of delivery. In order to achieve the effective delivery of nucleic acid drugs and exert gene regulation functions, it is often necessary to introduce specific vectors to help functional nucleic acids be delivered to target tissues and cells. Among them, although viral vectors have high transfection efficiency, they are also faced with a series of problems such as immunogenicity, insertion mutations, and complex preparation in the actual application process, which hinders their clinical transformation. In addition to viral vectors, non-viral vectors such as cationic liposomes and cationic polymers are also commonly used for the delivery of nucleic acid drugs, but cationic delivery vectors generally face problems such as high cytotoxicity and difficult quality control. Although each drug has its advantages, due to the complexity of the inflammatory response, the use of a single strategy to regulate a certain target or block a certain cytokine may lead to a compensatory increase in other proinflammatory cytokines, making it difficult to achieve satisfactory therapeutic effects. Summary of the invention
[0006] In view of this, the purpose of the present invention is to provide a small molecule drug-oligonucleotide conjugate and its application. The small molecule drug-oligonucleotide conjugate of the present invention contains both a small molecule drug for regulating immune response and a functional oligonucleotide molecule. The combined use of the two can simultaneously act on different inflammation-related signal pathways to produce a synergistic effect, thereby achieving better therapeutic effects.
[0007] The present invention provides a small molecule drug-oligonucleotide conjugate, which is obtained by covalently coupling a small molecule drug with immunomodulatory function and a functional oligonucleotide molecule capable of regulating the expression of inflammation-related genes.
[0008] Preferably, the small molecule drug and the functional oligonucleotide molecule are covalently coupled via a chemical linker.
[0009] Preferably, the selected small molecule drug is a small molecule drug that acts on immune-related signaling pathways and can regulate immune responses; preferably, the small molecule drug includes one or more of a calcineurin inhibitor, a glucocorticoid, an mTOR inhibitor, and a vitamin D analog.
[0010] Preferably, the inflammation-related genes include one or more of tumor necrosis factor-a gene, interleukin 1b gene, interleukin 17 gene, interleukin 23 gene, NFKBIZ gene, inflammasome NLRP3 gene, JAK gene and PDE4 gene.
[0011] Preferably, the functional oligonucleotide molecule comprises one of a double-stranded small interfering nucleic acid, a micronucleic acid and a single-stranded antisense oligonucleotide.
[0012] Preferably, when the functional oligonucleotide molecule is a double-stranded small interfering nucleic acid or micronucleic acid, the small molecule drug is covalently coupled to the 3' end of the sense chain of the functional oligonucleotide molecule; when the functional oligonucleotide molecule is a single-stranded antisense oligonucleotide, the small molecule drug is covalently coupled to the 3' end or 5' end of the single-stranded antisense oligonucleotide.
[0013] Preferably, the number of small molecule drugs covalently coupled to each functional oligonucleotide molecule is 1 to 40.
[0014] Preferably, the small molecule drug is covalently coupled to the end of the functional oligonucleotide molecule or the small molecule drug is covalently coupled to the side chain base or phosphate backbone of the 3' or 5' extension sequence of the functional oligonucleotide molecule;
[0015] Preferably, when the small molecule drug is covalently coupled to the end of the functional oligonucleotide molecule, the chemical structure of the small molecule drug-oligonucleotide conjugate is as shown in Formula 1 to Formula 14:
[0016]
[0017]
[0018] In the above formulae 1 to 14, L and T are each independently absent, -(CH2) h -or-(CH2) h - is a group formed by replacing any one or more alkylene groups in the formula (A); wherein h is 0 to 15; wherein the A group includes: -O-, -S-, -C(O)-, -C(O)O-, -C(O)NH-, -CH(R C )-, -C(R')(R”)-, -NH-, -N(R N )-, -SS-, -C(R')=C(R”)-, -C≡C-, One or more of; R in the A group C , R N, R', R" means that any one or more hydrogen atoms on the designated atom are replaced by a B group, provided that the normal valence of the designated atom is not exceeded and the substitution generates a stable compound, the designated atom includes a carbon atom or a nitrogen atom; the B group includes a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a cyano group, a hydroxyl group, an oxo group, a carboxyl group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, a heteroaryl group, an aryl group, a ketone group, an alkoxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group or a halogen group; the halogen group includes F, Cl, Br or I; (O) in the A group represents a carbonyl oxygen atom;
[0019] In Formulae 1 to 14, Q, Y, and Z are each independently absent, -O-, -S-, -C(O)-, -NH-, -CH2-, -C(O)NH-, -NHC(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)NH-, -NHC(O)O-, and One or more of; (O) in the Q, Y, Z groups represents a carbonyl oxygen atom; is the connection site;
[0020] In Formulae 1 to 14, G represents a small molecule immunomodulatory drug; m, n, and k are independently 1 to 15;
[0021] X represents O or S;
[0022] Preferably, when the small molecule drug is covalently coupled to the side chain base or phosphate backbone of the 3'-end or 5'-end extension sequence of the functional oligonucleotide molecule, the chemical structural formula of the small molecule drug-oligonucleotide conjugate is as shown in Formula 15 to Formula 20:
[0023]
[0024]
[0025] In the above formulae 15 to 20, T is each independently absent, -(CH2) h -or-(CH2) h - is a group formed by replacing any one or more alkylene groups in the formula (A); wherein h is 0 to 15; wherein the A group includes: -O-, -S-, -C(O)-, -C(O)O-, -C(O)NH-, -CH(R C )-, -C(R')(R”)-, -NH-, -N(R N )-, -SS-, -C(R')=C(R”)-, -C≡C-, One or more of; R in the A group C , R N, R', R" means that any one or more hydrogen atoms on the designated atom are replaced by a B group, provided that the normal valence of the designated atom is not exceeded and the substitution generates a stable compound, the designated atom includes a carbon atom or a nitrogen atom; the B group includes a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a cyano group, a hydroxyl group, an oxo group, a carboxyl group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, a heteroaryl group, an aryl group, a ketone group, an alkoxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group or a halogen group; the halogen group includes F, Cl, Br or I; (O) in the A group represents a carbonyl oxygen atom;
[0026] In Formulae 15 to 20, Y and Z are each independently absent, O, S, C(O), NH, CH2, C(O)NH, NHC(O), C(O)O, OC(O), OC(O)O, OC(O)NH, NHC(O)O, and One or more of; (O) in the Y and Z groups represents a carbonyl oxygen atom; is the connection site;
[0027] In the above formulae 15 to 20, G represents an immunomodulatory inhibitor; n is independently 1 to 15; m and i are independently 0 to 5; k and j are independently 1 to 20; R represents H; and B represents a nucleic acid base.
[0028] The present invention also provides the use of the small molecule drug-oligonucleotide conjugate described in the above scheme in the preparation of drugs for treating inflammation-related diseases.
[0029] Preferably, the inflammation-related diseases include one or more of dry eye, psoriasis, Sjögren's syndrome, uveitis, keratitis, conjunctivitis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease.
[0030] The present invention provides a small molecule drug-oligonucleotide conjugate, which is obtained by covalently coupling a small molecule drug with an immunomodulatory function and a functional oligonucleotide molecule capable of regulating the expression of inflammation-related genes. The present invention aims at the problems of poor water solubility and difficulty in drug delivery of existing small molecule immunomodulatory drugs, and adopts a method for coupling with oligonucleotide drugs. On the one hand, the excellent hydrophilicity of oligonucleotides can improve the solubility properties of small molecule drugs, improve their tissue distribution in the body, and promote delivery and absorption. At the same time, hydrophobic small molecule drugs can also promote the entry of oligonucleotides into cells, thereby enhancing their ability to regulate target genes. Secondly, the present invention achieves synergistic regulation of different targets of inflammatory response by co-delivering small molecule drugs and functional oligonucleotide molecules, thereby achieving better disease treatment effects and achieving safe and efficient medication. In addition, the two drug molecules assist each other, and the preparation of a new drug delivery system without the need for additional carriers can be realized, and functional oligonucleotide molecules and small molecule immunomodulatory drugs can be efficiently delivered at the same time, so as to achieve the purpose of synergistic regulation of inflammatory response, thereby providing a better solution for the treatment of various inflammatory-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 It is a azido-modified cyclosporine A (CsA-N3) and a monocyclosporine A-NFKBIZ antisense oligonucleotide covalent conjugate (CsA-ASO NFKBIZ ) Schematic diagram of the preparation route;
[0032] Figure 2 is the chloromethyl carbonate cyclosporine A (CsA-Cl) 1 HNMR spectrum;
[0033] Figure 3 is the chloromethyl carbonate cyclosporine A (CsA-Cl) 13 C NMR spectrum;
[0034] Figure 4 MALDI-TOF mass spectrum of chloromethyl carbonate cyclosporine A (CsA-Cl);
[0035] Figure 5 Cyclosporine A (CsA-N3) modified with azidohexanoic acid carbonate 1 HNMR spectrum;
[0036] Figure 6 The MALDI-TOF mass spectrum of cyclosporine A (CsA-N3) modified with azidohexanoic acid carbonate;
[0037] Figure 7 The gel electrophoresis diagram of the coupling product of CsA-N3 and DBCO-modified ASO was shown in Figure 1. 10% denaturing polyacrylamide gel electrophoresis confirmed that CsA-ASO NFKBIZ Efficient synthesis of conjugates;
[0038] Figure 8 CsA-ASO NFKBIZ-h Cellular uptake of the conjugate;
[0039] Fig. 9 Real-time fluorescence quantitative PCR detection of CsA-ASO NFKBIZ-h and the target gene NFKBIZ mRNA expression level after cells were treated with control samples;
[0040] Fig.10 CsA-ASO NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Sodium fluorescein staining of mouse eyes on days 0, 7, and 14 of treatment; (B) Data analysis of sodium fluorescein scores of mouse eyes on days 0, 7, and 14 of treatment; (C) Results of phenol red cotton thread tear test of mice on days 0, 7, and 14 of treatment;
[0041] Fig.11 2CsA-ASO NFKBIZ 10% denaturing polyacrylamide gel electrophoresis and 1% agarose gel electrophoresis of nanomicelles;
[0042] Fig.12 Real-time fluorescence quantitative PCR detection of 2CsA-ASO NFKBIZ-h and the target gene NFKBIZ mRNA expression level after cells were treated with control samples;
[0043] Fig.13 2CsA-ASO NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Sodium fluorescein staining of mouse eyes on days 0, 7, and 14 of treatment; (B) Data analysis of sodium fluorescein scores of mouse eyes on days 0, 7, and 14 of treatment; (C) Results of phenol red cotton thread tear test of mice on days 0, 7, and 14 of treatment;
[0044] Fig.14 3CsA-ASO NFKBIZ Characterization of the conjugate and its self-assembled nanomicelles. The left figure shows the results of 10% denaturing polyacrylamide gel electrophoresis, and the right figure shows the results of 0.5% agarose gel electrophoresis.
[0045] Fig.15 Real-time fluorescence quantitative PCR detection of 3CsA-ASO NFKBIZ-h and the target gene NFKBIZ mRNA expression level after cells were treated with control samples;
[0046] Fig.16 3CsA-ASO NFKBIZ-mEvaluation of the effect of nano-micelles in treating dry eyes; (A) Sodium fluorescein staining of mouse eyes on days 0, 7, and 14 of treatment; (B) Data analysis of sodium fluorescein scores of mouse eyes on days 0, 7, and 14 of treatment; (C) Results of phenol red cotton thread tear test of mice on days 0, 7, and 14 of treatment;
[0047] Fig.17 Schematic diagram of the synthesis of aminotris[(2-propynyloxy)methyl]methane;
[0048] Fig.18 is the hydrogen nuclear magnetic resonance spectrum of Boc-aminotris[(2-propynyloxy)methyl]methane;
[0049] Fig.19 CsA3-ASO NFKBIZ Schematic diagram of the synthesis of the conjugate;
[0050] Fig. 20 Characterization of triacetylenic modified ASO by 20% denaturing polyacrylamide gel electrophoresis NFKBIZ Conjugate;
[0051] Fig.21 Characterization of CsA3-ASO by 0.5% agarose gel electrophoresis NFKBIZ Nanomicelles;
[0052] Fig. 22 CsA3-ASO NFKBIZ Hydrated particle size (A) and morphology (B) of nanomicelles;
[0053] Fig.23 Real-time fluorescence quantitative PCR detection of CsA3-ASO NFKBIZ-h The target gene NFKBIZ mRNA expression level after cells were treated with nanomicelles and control samples;
[0054] Fig.24 CsA3-ASO NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Sodium fluorescein staining of mouse eyes on days 0 and 14 of treatment; (B) Data analysis of sodium fluorescein scores of mouse eyes on days 0 and 14 of treatment; (C) Results of phenol red cotton thread tear test of mice on days 0 and 14 of treatment;
[0055] Fig.25 CsA-siRNA NFKBIZ , 2CsA-siRNA NFKBIZ 3CsA-siRNA NFKBIZ 15% denaturing polyacrylamide gel electrophoresis results of conjugated molecules and 2CsA-siRNA NFKBIZ 3CsA-siRNA NFKBIZ 0.5% agarose gel electrophoresis results of nanomicelles;
[0056] Fig.26 Human corneal epithelial cells were expressed by CsA-siRNA NFKBIZ-h Conjugate, 2CsA-siRNA NFKBIZ-h Nanomicelles and 3CsA-siRNA NFKBIZ-h The expression level of IκB-ζ protein in cells after treatment with nanomicelles and control samples;
[0057] Fig. 27 Real-time fluorescence quantitative PCR detection of CsA-siRNA NFKBIZ-h Conjugate, 2CsA-siRNA NFKBIZ-h Nanomicelles and 3CsA-siRNA NFKBIZ-h NFKBIZ mRNA expression in human ocular epithelial cells after treatment with nanomicelles and control samples;
[0058] Fig.28 CsA-siRNA NFKBIZ-m Conjugate, 2CsA-siRNA NFKBIZ-m Nanomicelles and 3CsA-siRNA NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Sodium fluorescein staining of mouse eyes on days 0, 7, and 14 of treatment; (B) Data analysis of sodium fluorescein scores of mouse eyes on days 0, 7, and 14 of treatment; (C) Results of phenol red cotton thread tear test of mice on days 0, 7, and 14 of treatment;
[0059] Fig.29 This is a synthetic step of carboethyl bromide cyclosporine A; Fig.30 is the LC-MS spectrum of carboxyethyl bromide cyclosporine A;
[0060] Fig.31 20CsA-ASO NFKBIZ 10% denaturing polyacrylamide gel image and 1% agarose gel image of nanomicelles;
[0061] Fig.32 Real-time fluorescence quantitative PCR detection of 20CsA-ASO NFKBIZ-h The expression level of NFKBIZ mRNA in cells after nanomicelle and control sample treatment;
[0062] Fig.33 20CsA-ASO NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Data analysis of sodium fluorescein scores in mice eyes at 0 and 14 days after treatment; (B) Results of phenol red cotton thread tear test in mice at 0 and 14 days after treatment;
[0063] Fig.34Real-time fluorescence quantitative PCR was used to detect the expression of various inflammatory mRNAs in human corneal epithelial cells treated with different target 3CsA-siRNA nanomicelles and control samples;
[0064] Fig.35 ELISA was used to detect the expression of various inflammatory factors in human corneal epithelial cells treated with different target 3CsA-siRNA nanomicelles and control samples;
[0065] Fig.36 To evaluate the effect of 3CsA-siRNA nanomicelles on treating dry eyes at different targets; (A) Data analysis of sodium fluorescein scores in mice eyes at 0 and 14 days of treatment; (B) Results of phenol red cotton thread tear test in mice at 0 and 14 days of treatment;
[0066] Fig.37 Real-time fluorescence quantitative PCR was used to detect the expression of mRNA of various inflammatory targets in human corneal epithelial cells treated with different target 3CsA-siRNA nanomicelles and control samples;
[0067] Fig.38 To evaluate the effect of 3CsA-siRNA nanomicelles on treating dry eyes at different targets; (A) Data analysis of sodium fluorescein scores in mice eyes at 0 and 14 days of treatment; (B) Results of phenol red cotton thread tear test in mice at 0 and 14 days of treatment;
[0068] Fig.39 Real-time fluorescence quantitative PCR was used to detect the expression of different inflammatory mRNAs in human corneal epithelial cells after being treated with 3CsA-ASO nanomicelles with different targets and control samples;
[0069] Fig.40 ELISA was used to detect the expression of different inflammatory factors in human corneal epithelial cells after being treated with 3CsA-ASO nanomicelles at different targets and control samples;
[0070] Fig.41 Evaluation of the effect of 3CsA-ASO nano-micelles with different targets on the treatment of dry eyes; (A) Data analysis of sodium fluorescein scores in mice eyes at 0 and 14 days of treatment; (B) Results of phenol red cotton thread tear test in mice at 0 and 14 days of treatment;
[0071] Fig.42 Real-time fluorescence quantitative PCR was used to detect the expression of various inflammatory mRNAs in human corneal epithelial cells after being treated with different target 20CsA-ASO nanomicelles and control samples;
[0072] Fig.43Evaluation of the effect of 20CsA-ASO nano-micelles with different targets on the treatment of dry eyes; (A) Data analysis of sodium fluorescein scores in mice eyes at 0 and 14 days of treatment; (B) Results of phenol red cotton thread tear test in mice at 0 and 14 days of treatment;
[0073] Fig.44 Schematic diagram of the synthesis of RAP-Bz-Br;
[0074] Fig.45 The H NMR spectrum (A) and C NMR spectrum (B) of TK-Bz-Br;
[0075] Fig.46 The H NMR spectrum (A) and C NMR spectrum (B) of RAP-31-O-TMS-42-Bz-Br;
[0076] Fig.47 15% denaturing polyacrylamide gel electrophoresis (A) and 1% agarose gel electrophoresis (B) characterize the successful preparation of 10RAP-ASO conjugates and 10RAP-nanomicelles;
[0077] Fig.48 For 10RAP-ASO NFKBIZ Hydrated particle size (left) and transmission electron microscopy morphology (right) of nanomicelles;
[0078] Fig.49 Real-time quantitative PCR (RT-qPCR) was used to detect the mRNA expression level of NFKBIZ;
[0079] Fig.50 10RAP-ASO for different targets NFKBIZ-m Evaluation of the effect of nano-micelles in treating dry eyes; (A) Data analysis of sodium fluorescein scores in mice eyes at 0, 7, and 14 days of treatment; (B) Results of phenol red cotton thread tear test in mice at 0, 7, and 14 days of treatment;
[0080] Fig.51 RT-PCR detection of CsA3-ASO NFKBIZ-h The expression of NFKBIZ mRNA in cells after co-incubation of nanomicelles and control samples with HaCaT cells;
[0081] Fig.52 CsA3-ASO was detected by ELISA NFKBIZ-h Secretion of different inflammatory factors in HaCaT cells after treatment with nanomicelles and control samples;
[0082] Fig.53 This is a model phenotype diagram of the mouse back on the 7th day of modeling;
[0083] Fig.54The photos of skin lesions on the back of psoriasis-like model mice on days 0 and 7 after drug application treatment;
[0084] Fig.55 The changes in ear and back skin thickness of psoriasis-like model mice after smear drug administration;
[0085] Fig.56 The scores of erythema, scaling, and skin thickening on the back lesions of psoriasis-like model mice after smear drug treatment and the severity index score of psoriasis lesion area;
[0086] Fig.57 Schematic diagram of the synthesis of carbonylethyl triamcinolone acetonide bromide (TA-Br);
[0087] Fig.58 is the H NMR spectrum of TA-Br;
[0088] Fig.59 is the carbon NMR spectrum of TA-Br;
[0089] Fig.60 is the LC-MS spectrum of TA-Br;
[0090] Fig.61 Characterization of 10TA-ASO by 15% denaturing polyacrylamide gel electrophoresis NFKBIZ Successful preparation of conjugates;
[0091] Fig.62 Characterization of 10TA-ASO by 1% agarose gel electrophoresis NFKBIZ The successful preparation of nanomicelles;
[0092] Fig.63 10TA-ASO for RT-PCR detection NFKBIZ-h The expression of NFKBIZ mRNA in cells after co-incubation of nanomicelles and control samples with HaCaT cells;
[0093] Fig.64 The changes in ear and back skin thickness of psoriasis-like model mice after smear drug administration;
[0094] Fig.65 The scores of erythema, scaling, and skin thickening on the back lesions of mice before and after treatment, as well as the psoriasis lesion area severity index score;
[0095] Fig.66 The photos are of skin lesions on the back of psoriasis-like model mice at 0 and 7 days of treatment;
[0096] Fig.67 Schematic diagram of the synthesis of Cal-Bz-Br;
[0097] Fig.68is the H NMR spectrum of DTPA-Bz-Br;
[0098] Fig.69 is the H NMR spectrum of Cal-Bz-Br;
[0099] Fig.70 is the LC-MS spectrum of Cal-Bz-Br;
[0100] Fig.71 Characterization of 10Cal-ASO by 15% denaturing polyacrylamide gel electrophoresis NFKBIZ Successful preparation of conjugates;
[0101] Fig.72 Characterization of 10Cal-ASO by 1% agarose gel electrophoresis NFKBIZ The successful preparation of nanomicelles;
[0102] Fig.73 10Cal-ASO NFKBIZ Hydrated particle size (left) and transmission electron microscopy morphology (right) of nanomicelles;
[0103] Fig.74 10Cal-ASO NFKBIZ Critical micelle concentration diagram of nanomicelles;
[0104] Fig.75 10Cal-ASO for RT-PCR detection NFKBIZ-h The expression of NFKBIZ mRNA in cells after co-incubation of nanomicelles and control samples with HaCaT cells;
[0105] Fig.76 Changes in skin thickness during treatment in psoriasis-like model mice;
[0106] Fig.77 The scores of erythema, scaling, and skin thickening on the back lesions of mice before and after treatment, as well as the psoriasis lesion area severity index score;
[0107] Fig.78 These are photos of skin lesions on the back of psoriasis-like model mice on days 0 and 7 of treatment. DETAILED DESCRIPTION
[0108] The present invention provides a small molecule drug-oligonucleotide conjugate, which is obtained by covalently coupling a small molecule drug with immunomodulatory function and a functional oligonucleotide molecule capable of regulating the expression of inflammation-related genes.
[0109] In the present invention, the small molecule drug and the functional oligonucleotide molecule are preferably covalently coupled via a chemical linker.
[0110] In the present invention, the selected small molecule drugs are preferably small molecule drugs that act on immune-related signaling pathways and can regulate immune responses; in the present invention, the small molecule drugs include one or more of calcineurin inhibitors, glucocorticoids, mTOR inhibitors and vitamin D analogs. In the present invention, the calcineurin inhibitor preferably includes cyclosporine A, tacrolimus, sirolimus, pimecrolimus or analogs of cyclosporine A, tacrolimus, sirolimus or pimecrolimus; the mTOR inhibitor preferably includes rapamycin or a derivative of rapamycin; the derivative of rapamycin preferably includes Temsirolimus (CCI-779) or Everolimus (RAD001); the glucocorticoid preferably includes triamcinolone acetonide, dexamethasone, betamethasone, methylprednisolone, cortisone, hydrocortisone, prednisone acetate, prednisolone acetate, prednisone or analogs of triamcinolone acetonide, dexamethasone, betamethasone, methylprednisolone, cortisone, hydrocortisone, prednisone acetate, prednisolone acetate, prednisone; the vitamin D analog preferably includes calcipotriol, calcitriol, calcifediol, alfacalcidol or paricalcitol.
[0111] In the present invention, the inflammation-related genes include one or more of tumor necrosis factor-a (TNF-a) gene, interleukin 1b (IL-1b) gene, interleukin 17 (IL-17) gene, interleukin 23 (IL-23) gene, NFKBIZ gene, inflammasome NLRP3 gene, JAK gene and PDE4 gene. Functional oligonucleotide molecules corresponding to the above-mentioned key genes of inflammatory response are designed to regulate their expression, and each gene has its corresponding functional oligonucleotide molecule to regulate the expression of the corresponding mRNA of the gene.
[0112] In the present invention, the functional oligonucleotide molecule includes one of double-stranded small interfering nucleic acid (siRNA), micronucleic acid (miRNA) and single-stranded antisense oligonucleotide (ASO). In the present invention, the functional oligonucleotide molecule used can be an unmodified functional oligonucleotide molecule or a functional oligonucleotide molecule modified with stability enhancement; the stability enhancement modification preferably includes one or more of PS, 2-position OMe, MOE and F generation modification.
[0113] In the present invention, the combinations of the small molecule drugs and functional oligonucleotide molecules are various and not mutually restricted. One small molecule drug can be coupled with multiple functional oligonucleotide molecules, and one functional oligonucleotide molecule can also be coupled with multiple small molecule drugs to achieve different application purposes.
[0114] In the present invention, when the functional oligonucleotide molecule is a double-stranded small interfering nucleic acid or micronucleic acid, the small molecule drug is covalently coupled to the 3' end of the sense chain of the functional oligonucleotide molecule; when the functional oligonucleotide molecule is a single-stranded antisense oligonucleotide, the small molecule drug is covalently coupled to the 3' end or 5' end of the single-stranded antisense oligonucleotide.
[0115] In the present invention, the small molecule drug is covalently coupled to the end of the functional oligonucleotide molecule or the small molecule drug is covalently coupled to the side chain base or phosphate backbone of the 3' or 5' extension sequence of the functional oligonucleotide molecule. In the present invention, the number of small molecule drugs covalently coupled to each functional oligonucleotide molecule is preferably any integer value from 1 to 40. When the small molecule drug is covalently coupled to the end of the functional oligonucleotide molecule, the number of small molecule drugs covalently coupled to each functional oligonucleotide molecule is preferably any integer value from 1 to 6; when the small molecule drug is covalently coupled to the side chain base or phosphate backbone of the 3' or 5' extension sequence of the functional oligonucleotide molecule, the number of small molecule drugs covalently coupled to each functional oligonucleotide molecule is preferably any integer value from 1 to 20.
[0116] In the present invention, when the small molecule drug is covalently coupled to the end of the functional oligonucleotide molecule, the chemical structural formula of the small molecule drug-oligonucleotide conjugate is as shown in Formula 1 to Formula 14:
[0117]
[0118]
[0119]
[0120] In the above formulae 1 to 14, L and T are each independently absent, -(CH2) h -or-(CH2) h - is a group formed by replacing any one or more alkylene groups in the formula (A); wherein h is 0 to 15; wherein the A group includes: -O-, -S-, -C(O)-, -C(O)O-, -C(O)NH-, -CH(R C )-, -C(R')(R”)-, -NH-, -N(R N )-, -SS-, -C(R')=C(R”)-, -C≡C-, One or more of; R in the A group C , R N, R', R" means that any one or more hydrogen atoms on the designated atom are replaced by a B group, provided that the normal valence of the designated atom is not exceeded and the substitution generates a stable compound, the designated atom includes a carbon atom or a nitrogen atom; the B group includes a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a cyano group, a hydroxyl group, an oxo group, a carboxyl group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, a heteroaryl group, an aryl group, a ketone group, an alkoxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group or a halogen group; the halogen group includes F, Cl, Br or I; (O) in the A group represents a carbonyl oxygen atom;
[0121] In Formulae 1 to 14, Q, Y, and Z are each independently absent, -O-, -S-, -C(O)-, -NH-, -CH2-, -C(O)NH-, -NHC(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)NH-, -NHC(O)O-, and One or more of; (O) in the Q, Y, Z groups represents a carbonyl oxygen atom; is the connection site;
[0122] In Formulae 1 to 14, G represents a small molecule immunomodulatory drug; m, n, and k are independently 1 to 15;
[0123] X represents O or S;
[0124] Preferably, when the small molecule drug is covalently coupled to the side chain base or phosphate backbone of the 3'-end or 5'-end extension sequence of the functional oligonucleotide molecule, the chemical structural formula of the small molecule drug-oligonucleotide conjugate is as shown in Formula 15 to Formula 20:
[0125]
[0126]
[0127] In the above formulae 15 to 20, T is each independently absent, -(CH2) h -or-(CH2) h - is a group formed by replacing any one or more alkylene groups in the group by an A group; wherein h is 0 to 15; wherein (O) in the A group represents a carbonyl oxygen atom; wherein the A group includes: -O-, -S-, -C(O)-, -C(O)O-, -C(O)NH-, -CH(R C )-, -C(R')(R”)-, -NH-, -N(R N )-, -SS-, -C(R')=C(R”)-, -C≡C-, One or more of; R in the A group C , RN , R', R" means that any one or more hydrogen atoms on the designated atom are replaced by a B group, provided that the normal valence of the designated atom is not exceeded and the substitution generates a stable compound, the designated atom includes a carbon atom or a nitrogen atom; the B group includes a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a cyano group, a hydroxyl group, an oxo group, a carboxyl group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, a heteroaryl group, an aryl group, a ketone group, an alkoxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group or a halogen group; the halogen group includes F, Cl, Br or I; (O) in the A group represents a carbonyl oxygen atom;
[0128] In Formulae 15 to 20, Y and Z are each independently absent, O, S, C(O), NH, CH2, C(O)NH, NHC(O), C(O)O, OC(O), OC(O)O, OC(O)NH, NHC(O)O, and
[0129] One or more of; (O) in the Y and Z groups represents a carbonyl oxygen atom; is the connection site;
[0130] In the above formulae 15 to 20, G represents an immunomodulatory inhibitor; n is independently 1 to 15; m and i are independently 0 to 5; k and j are independently 1 to 20; R represents H; and B represents a nucleic acid base.
[0131] The present invention also provides a method for preparing the small molecule drug-oligonucleotide conjugate described in the above scheme, comprising the following steps:
[0132] The small molecule drug with immunomodulatory function and the functional oligonucleotide molecule capable of regulating the expression of inflammation-related genes are covalently coupled to obtain a small molecule drug-oligonucleotide conjugate. The present invention has no particular limitation on the specific method of covalently coupling the small molecule drug and the functional oligonucleotide molecule, and a conventional coupling method in the art can be used.
[0133] In the present invention, the reaction types involved in the covalent coupling preferably include one or more of esterification, amidation, click chemistry, electrophilic substitution, and nucleophilic substitution or Diels-Alder reaction.
[0134] The present invention also provides the use of the small molecule drug-oligonucleotide conjugate described in the above scheme in the preparation of drugs for treating inflammation-related diseases.
[0135] In the present invention, the inflammation-related diseases include one or more of psoriasis, dry eye, Sjögren's syndrome, uveitis, keratitis, conjunctivitis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease.
[0136] The present invention utilizes the hydrophilic property of functional oligonucleotide molecules to promote the dissolution of hydrophobic small molecule drugs with immunomodulatory functions in aqueous solution, so that they can be well dispersed in buffer solutions and efficiently taken up by cells without the use of other cosolvents. The increase in solubility can reduce the concentration used during administration and reduce the toxic and side effects of drug molecules. At the same time, the modification of hydrophobic small molecule drugs also makes the functional oligonucleotide molecules have certain hydrophobic properties. When there are more hydrophobic drugs, small molecule drug-oligonucleotide conjugates can be further assembled into micelles, thereby promoting the cell's uptake of small molecule drug-oligonucleotide conjugates, overcoming the problem of difficulty in nucleic acid drug entry into cells. The small molecule drug-oligonucleotide conjugate of the present invention simultaneously comprises a small molecule drug that regulates immune response and a functional oligonucleotide molecule. The combined use of the two can act on different inflammation-related signaling pathways at the same time, produce a synergistic effect, solve the problem of poor efficacy of using small molecule immunomodulatory drugs or oligonucleotide drugs alone, thereby achieving better therapeutic effects.
[0137] In one embodiment of the present invention, the present invention constructs a single cyclosporine A (CsA) molecule and an antisense oligonucleotide (ASO) targeting the nuclear factor κB inhibitor ζ (NFKBIZ) gene. NFKBIZ ) covalently coupled to form a CsA-NFKBIZ antisense oligonucleotide conjugate (CsA-ASO NFKBIZ In the present invention, the CsA-NFKBIZ antisense oligonucleotide conjugate can be used to prepare a drug for treating dry eye. NFKBIZ Covalent conjugates can achieve the synergistic treatment of dry eye with small molecule immunomodulatory drugs and nucleic acid drugs. CsA, as a commonly used immunosuppressant, can inhibit the production and release of proinflammatory cytokines by inhibiting the activity of calcineurin, and has been used clinically to treat the symptoms and signs of dry eye. Antisense oligonucleotides (ASOs) targeting the NFKBIZ gene NFKBIZ ) can effectively knock down the expression of NFKBIZ gene in corneal epithelial cells, further reduce the level of cell inflammation, and regulate immune balance. NFKBIZ In the covalent conjugate, small molecule drugs and nucleic acid drugs act on different targets of the inflammatory signaling pathway to achieve synergistic treatment of dry eye disease and achieve better therapeutic effects. The present invention uses the strong hydrophilicity of nucleic acid molecules to give the small molecule drug CsA good water solubility after coupling, so that it can be efficiently taken up by cells without the help of other adjuvants, exert its efficacy faster, reduce the drug concentration during treatment, and thus reduce the possible toxic side effects of the drug. At the same time, the prepared CsA-ASO NFKBIZ The covalent conjugate can enhance its interaction with cells due to the presence of hydrophobic CsA. Compared with unmodified antisense oligonucleotides, CsA-ASO NFKBIZThe conjugate can be better internalized by cells, thus playing a better role in gene regulation. Ultimately, through the dual inflammation regulation of CsA and antisense oligonucleotides, a good dry eye treatment effect is achieved.
[0138] In one embodiment of the present invention, the present invention constructs a NFKBIZ antisense oligonucleotide (ASO NFKBIZ ) small molecule drug-antisense oligonucleotide conjugate (2CsA-ASO NFKBIZ ), and utilize its amphiphilicity to form a nano-micelle assembly structure through self-assembly for co-delivery of CsA and NFKBIZ antisense oligonucleotides; the 2CsA-ASO NFKBIZ It can be used to prepare drugs for treating dry eye. The present invention uses small molecule drugs CsA and antisense oligonucleotide drugs to synergistically treat dry eye, and simultaneously acts on different targets of the inflammatory signaling pathway to synergistically reduce the level of cellular inflammation; secondly, the case name uses the hydrophilicity of nucleic acids to give immune-modulating small molecule drugs better water solubility, and at the same time uses the hydrophobicity of CsA to enhance the interaction between the coupling product and cells, thereby improving the drug delivery efficiency; thirdly, compared with the CsA-ASO prepared by coupling a single CsA molecule with an ASO targeting the NFKBIZ gene, NFKBIZ The covalent conjugate can be dissolved in aqueous solution as a single molecule. The 2CsA-ASO formed by the coupling of two CsA small molecules NFKBIZ The covalent conjugate exhibits amphiphilicity due to the increase in the amount of hydrophobic CsA, and can be assembled into a nano-micelle structure in the solution. The center of the nano-micelle is a hydrophobic CsA molecule, and the outer shell is a water-soluble antisense oligonucleotide molecule. The assembled nano-micelles can efficiently transfect cells without any transfection reagents, achieving efficient co-delivery of CsA and antisense oligonucleotides, thereby achieving a good synergistic treatment effect for dry eye.
[0139] In one embodiment of the present invention, the present invention constructs an antisense oligonucleotide targeting the NFKBIZ gene modified by three cyclosporine A molecules to prepare a tricyclosporine A-NFKBIZ antisense oligonucleotide conjugate (3CsA-ASO NFKBIZ ), and utilize its amphiphilicity to form 3CsA-ASO through self-assembly NFKBIZThe nano-micelle assembly structure is used for the co-delivery of CsA and antisense oligonucleotides targeting the NFKBIZ gene, and then for the synergistic treatment of dry eye. The present invention uses small molecule drugs and nucleic acid drugs to act on different targets of the inflammatory signaling pathway to synergistically reduce the level of cellular inflammation; the hydrophilicity of nucleic acids is used to give immunomodulatory small molecule drugs better water solubility, and the hydrophobicity of CsA is used to enhance the interaction between the coupling product and cells, thereby improving the utilization efficiency of the drug; compared with a single or two CsA molecules and an ASO conjugate targeting the NFKBIZ gene, the drug-nucleic acid conjugate 3CsA-ASO after three CsA small molecules are coupled NFKBIZ After coupling with nucleic acid, it exhibits stronger amphiphilicity and is easier to assemble into nanomicelles in solution, making 3CsA-ASO NFKBIZ Nanomicelles are more likely to interact with cells, thereby achieving better synergistic treatment effects for dry eyes.
[0140] In one embodiment of the present invention, the present invention constructs a cyclosporine A trimer molecule and an antisense oligonucleotide (ASO) targeting NFKBIZ. NFKBIZ ) covalently coupled to form a cyclosporine A-antisense oligonucleotide conjugate (CsA3-ASO NFKBIZ ), and explore the spherical nanomicelles formed by their self-assembly for the synergistic treatment of dry eye. The present invention grafts three cyclosporine A at the end of ASO through a click chemistry reaction, and its purification and preparation method is simple and controllable. The strong hydrophobicity of the three cyclosporine A molecules is used to make the conjugate have strong amphiphilicity. The prepared conjugated product can self-assemble in an aqueous solution to form a stable nanomicelle structure with a low critical micelle concentration. The spherical nucleic acid micelle nanostructure can be efficiently taken up by cells to achieve simultaneous co-delivery of CsA and ASO; cyclosporine A, as an immunomodulator and anti-inflammatory drug, can inhibit the generation and release of pro-inflammatory cytokines, and increase the release level of anti-inflammatory cytokines. It can effectively improve the symptoms and signs of dry eye caused by long-term inflammation clinically; at the same time, ASO can knock down the expression of the inflammation-related gene NFKBIZ protein, further inhibiting the inflammatory response of dry eye. The synergistic regulatory effect inhibits the inflammatory response, regulates the immune balance, and achieves a better treatment effect for dry eye.
[0141] In one embodiment of the present invention, the present invention constructs single, double, and triple cyclosporin A and small interfering RNA (siRNA) targeting NFKBIZ gene. NFKBIZ) are covalently coupled to form a drug-nucleic acid conjugate, and the prepared conjugate or its assembled nanostructure is used to further achieve the synergistic treatment of dry eye. The present invention uses small molecule drugs and nucleic acid drugs to synergistically treat dry eye. CsA is an immunomodulator and anti-inflammatory drug that can inhibit the generation and release of pro-inflammatory cytokines. It can effectively improve the symptoms and signs of dry eye caused by long-term inflammation clinically; at the same time, NFKBIZ siRNA can knock down the expression of NFKBIZ in corneal epithelial cells, further reducing the level of cellular inflammation; the hydrophilic characteristics of siRNA are used to give CsA drugs better water solubility, reduce the concentration used during systemic application, and thus reduce toxic side effects. At the same time, the hydrophobic immunomodulatory small molecule drug CsA makes the conjugate of the two easier to interact with cells, improves the problem of RNA drugs entering cells, and thus achieves better treatment effects for dry eye. This embodiment is intended to expand the category of drug-nucleic acid conjugates for dry eye treatment.
[0142] In one embodiment of the present invention, the present invention constructs an antisense oligonucleotide (ASO) targeting the NFKBIZ gene by modifying multiple cyclosporin A molecules by phosphorothioate grafting. NFKBIZ ) to construct drug-antisense oligonucleotide conjugates, and use their amphiphilic self-assembly to form nanomicelles for the synergistic treatment of dry eye. This structure can not only achieve the NFKBIZ Synergistic treatment of dry eye disease can enhance the water solubility of cyclosporine A and the stability of nucleic acid drugs, and incubate the drug-nucleic acid conjugate to better interact with cells. At the same time, in this embodiment, 20 cyclosporine A molecules grafted ASO NFKBIZ The structure is assembled into nanomicelles with a smaller CMC value, carrying more therapeutic small molecule drugs, and achieving better therapeutic effects.
[0143] In one embodiment of the present invention, three CsA molecules were constructed and respectively combined with siRNA targeting IL-17. IL -17, siRNA targeting IL-1β IL-1β , siRNA targeting IL-23 IL-23 , and siRNA targeting TNF-α TNF -α covalent conjugation modification prepared small molecule drug-nucleic acid conjugates and their self-assembled nano-micelles are used for the synergistic treatment of dry eye. In this example, tricyclosporine A and small interfering RNA drug-nucleic acid conjugate nano-micelles with different inflammatory factor targets were prepared for the synergistic treatment of dry eye. The gene targets selected in this example are different inflammatory factors secreted by cells outside the cell, which further verifies the multi-target feasibility of this structure in the treatment of dry eye disease.
[0144] In one embodiment of the present invention, three CsA molecules were constructed and respectively combined with siRNA targeting NLRP3. NLRP3 , siRNA targeting JAK1 JAK1 , and siRNA targeting PDE4 PDE4 Small molecule drug-nucleic acid conjugates prepared by covalent coupling modification and their self-assembled nano-micelles are used for the synergistic treatment of dry eye. This example prepares a conjugate of siRNA targeting key genes related to inflammation in cells and cyclosporine A molecules, and uses its amphiphilic assembly to form nano-micelles for the synergistic treatment of dry eye. This example selects different inflammatory gene targets in cells to further verify the multi-target feasibility of this structure in the treatment of dry eye diseases.
[0145] In one embodiment of the present invention, the present invention constructs 3CsA and ASO IL-17 , 3CsA and ASO IL-1β , 3CsA and ASO IL-23 and 3CsA and ASO TNF-α Co-delivery of drug-nucleic acid conjugate self-assembled nanomicelles for synergistic treatment of dry eye disease. In this example, tricyclosporine A and antisense oligonucleotide drug-nucleic acid conjugate nanomicelles with different inflammatory factor targets were prepared for synergistic treatment of dry eye disease. The gene targets selected in this example are different inflammatory factors secreted by cells outside the cell, which further verifies the multi-target feasibility of this structure in the treatment of dry eye disease.
[0146] In one embodiment of the present invention, the present invention constructs 20CsA and ASO NLRP3 , 20CsA and ASO JAK1 and 20CsA and ASO PDE4 Co-delivery of drug-nucleic acid conjugate nano-micelles for synergistic treatment of dry eye disease. This example uses 20PS-modified ASO and grafts it with multiple cyclosporine A small molecules, which increases the drug loading while reducing the therapeutic dose and improves the safety of treatment; at the same time, this example selects multiple intracellular inflammatory treatment targets in dry eye disease to further demonstrate the multi-target feasibility of inflammatory drug-nucleic acid conjugates for the treatment of dry eye disease.
[0147] In one embodiment of the present invention, the present invention constructs a small molecule drug-antisense oligonucleotide conjugate (10RAP-ASO) obtained by modifying 10 rapamycin (RAP)-modified antisense oligonucleotides targeting the NFKBIZ gene. NFKBIZ) and the nano-micelles formed by self-assembly are used for the synergistic treatment of dry eye. The rapamycin-antisense oligonucleotide conjugate constructed by grafting multiple rapamycin molecules on the nucleic acid backbone at one end of the ASO sequence of the present invention has a high drug loading. The hydrophobicity of the rapamycin molecule and the hydrophilicity of the nucleic acid molecule are used to give the rapamycin-antisense oligonucleotide conjugate an amphiphilic characteristic, which can be self-assembled in an aqueous solution to form a nano-micelle structure. The nano-micelle structure can be effectively taken up by cells without other carrier materials, thereby achieving efficient co-delivery of rapamycin and antisense oligonucleotides; the rapamycin-antisense oligonucleotide conjugate can achieve the combined treatment of dry eye by regulating different inflammation-related signal pathways. Among them, rapamycin as a rapamycin target protein (mTOR) inhibitor can effectively inhibit the mTOR signal transduction pathway to achieve an inflammatory inhibitory effect, while the antisense oligonucleotide targeting the NFKBIZ gene can effectively knock down the expression of the NFKBIZ gene, further inhibiting the inflammatory response associated with dry eye. The inflammatory response is jointly inhibited by the synergistic action of the two, thereby achieving a good dry eye treatment effect.
[0148] In one embodiment of the present invention, the present invention constructs a cyclosporine A trimer (CsA3) and an antisense oligonucleotide (ASO) targeting NFKBIZ. NFKBIZ ) Small molecule drug-antisense oligonucleotide conjugates formed by covalent coupling and spherical nanomicelles formed by self-assembly are used for the synergistic treatment of psoriasis. The present invention grafts three cyclosporine A on the end of ASO through click chemistry reaction, and its purification and preparation method is simple and controllable. The strong hydrophobicity of the three cyclosporine A molecules makes the conjugate have strong amphiphilicity, and it can self-assemble in aqueous solution to form a stable nanomicelle structure without a carrier. The prepared spherical micelle nucleic acid nanostructure can be efficiently taken up by cells to achieve simultaneous co-delivery of CsA and ASO; cyclosporine A, as an immunomodulator and anti-inflammatory drug, can inhibit the generation and release of pro-inflammatory cytokines and increase the release level of anti-inflammatory cytokines; at the same time, ASO can knock down the expression of inflammation-related gene NFKBIZ protein, further inhibiting the inflammatory response of psoriasis. The synergistic regulatory effect can inhibit the inflammatory response, regulate the immune balance, and achieve a better treatment effect for psoriasis.
[0149] In one embodiment of the present invention, the present invention constructs a small molecule drug-antisense oligonucleotide conjugate of an antisense oligonucleotide (ASO) targeting the NFKBIZ gene modified by 10 triamcinolone acetonide molecules and the nano-micelle nanostructure formed by its assembly for the synergistic treatment of psoriasis. The triamcinolone acetonide-antisense oligonucleotide conjugate constructed by grafting multiple triamcinolone acetonide molecules at the end of the ASO sequence has a high drug loading capacity. The hydrophobicity of triamcinolone acetonide and the hydrophilicity of nucleic acid molecules are used to give the triamcinolone acetonide-antisense oligonucleotide conjugate amphiphilicity, and a nano-micelle structure can be formed by self-assembly in an aqueous solution. The nano-micelle structure can achieve efficient co-delivery of triamcinolone acetonide and antisense oligonucleotide without other carrier materials, and can be effectively taken up by cells; the combined treatment of psoriasis is achieved by regulating different inflammation-related signal pathways, wherein triamcinolone acetonide, as a glucocorticoid, has anti-inflammatory, anti-itching and vasoconstriction effects, and its anti-inflammatory and anti-allergic effects in the treatment of skin diseases are strong and lasting. At the same time, ASO targeting the NFKBIZ gene can effectively knock down the expression of NFKBIZ protein, further inhibiting the inflammatory response associated with psoriasis. The synergistic effect of the two combined to inhibit the inflammatory response, thus achieving a good psoriasis treatment effect.
[0150] In one embodiment of the present invention, the present invention constructs a small molecule drug-antisense oligonucleotide conjugate (10Cal-ASO) prepared by covalently coupling 10 calcipotriol molecules with an antisense oligonucleotide (ASO) targeting the NFKBIZ gene. NFKBIZ ) and the nano-micelles formed by their assembly are used for the synergistic treatment of psoriasis. The calcipotriol-antisense oligonucleotide conjugate constructed by grafting multiple calcipotriol molecules at the end of the ASO sequence of the present invention has a high drug loading capacity. The hydrophobicity of calcipotriol and the hydrophilicity of nucleic acid molecules are used to give the calcipotriol-antisense oligonucleotide conjugate amphiphilicity, and a nano-micelle structure can be formed by self-assembly in an aqueous solution. The nano-micelle structure can achieve efficient co-delivery of calcipotriol and antisense oligonucleotide without other carrier materials, and can be effectively taken up by cells; the combined treatment of psoriasis is achieved by regulating different inflammation-related signal pathways, wherein calcipotriol is an analog of vitamin D3, which can inhibit the proliferation of skin cells (keratinocytes) and induce their differentiation, thereby correcting the hyperplasia and differentiation abnormalities of psoriasis lesions. At the same time, ASO targeting the NFKBIZ gene can effectively knock down the expression of NFKBIZ protein, further inhibiting the inflammatory response associated with psoriasis. The inflammatory response is jointly inhibited by the synergistic action of the two, thereby achieving a good psoriasis treatment effect.
[0151] Unless otherwise specified, the present invention has no special requirements on the sources of the raw materials used, and commercially available products known to those skilled in the art may be used.
[0152] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of protection of the present invention. Improvements and adjustments made by those skilled in the art in practical applications according to the present invention still belong to the scope of protection of the present invention.
[0153] Example 1: Synergistic treatment of dry eye disease with cyclosporine A (CsA) and antisense oligonucleotide conjugate targeting nuclear factor κB inhibitor ζ (NFKBIZ)
[0154] 1.1 Synthesis of cyclosporine A modified with azidohexanoic acid carbonate (CsA-N3)
[0155] In this example, azidohexanoic acid carbonate modified cyclosporin A (CsA-N3) and CsA-ASO NFKBIZ The preparation route of covalent conjugates is as follows Figure 1 shown.
[0156] 1.1.1 Synthesis of chloromethyl carbonate cyclosporine A (CsA-Cl)
[0157] Under nitrogen protection, cyclosporin A (1000 mg) was placed in a dry 50 mL round-bottom flask, 10 mL of anhydrous dichloromethane was added and stirred until dissolved, the reaction bottle was placed in an ice bath, and then 592 μL of chloromethyl chloroformate was added dropwise, and then 336 μL of anhydrous pyridine was added dropwise, and the reaction was naturally restored to room temperature and stirred for 24 hours. After the reaction was completed, 40 mL of anhydrous dichloromethane was added to dilute the reaction solution, and the solution was washed with 50 mL of saturated sodium bicarbonate solution 3 times and 50 mL of saturated sodium chloride solution once, and the organic phase was collected and dried with anhydrous sodium sulfate, and the organic phase was concentrated by vacuum distillation and then separated and purified by silica gel column chromatography, and the eluent was petroleum ether / ethyl acetate, and finally 550 mg of white solid was obtained, that is, chloromethyl carbonate cyclosporin A was obtained, and the yield was ~60%.
[0158] Chloromethyl carbonate of cyclosporine A 1 HNMR spectrum Figure 2As shown, the solvent used in the NMR spectrum test was CDCl3, and the attribution of each proton peak is as follows: δ (ppm): 8.46 (1H, d), 7.91 (1H, d), 7.46 (1H, d), 7.37 (1H, d), 5.72 (1H, d), 5.62 (1H, dd), 5.47 (1H, d), 5.31 (2H, m), 5.21 (2H, m), 5. 06(2H,m),5.00(1H,q),4.88(1H,t),4.77(1H,t),4.70(1H,t),4.60(1H,d),4.33( 1H,t),4.05(1H,q),3.39(3H,s),3.25(3H,s),3.16(3H,s),3.13(1H,s),3.01(3H,d ),2.60(3H,d),2.34(1H,m),2.06(4H,m),2.00(4H,m),1.92(2H,m),1.81(3H,m),1 .66(6H,m),1.53(4H,d),1.42(2H,m),1.34(1H,m),1.26(3H,d),1.20(3H,d),1.14( 1H,dq),1.05(3H,d),1.04(1H,d),0.98(3H,t),0.94(3H,d),0.91(3H,d),0.89(3H,d),0.88(3H,d),0.86(3H,d),0.82(9H,m),0.81(3H,d),0.76(3H,d). Chloromethyl carbonate cyclosporine A 13 C NMR spectrum Figure 3 As shown, the solvent used in the nuclear magnetic spectrum test is CDCl3, and the characteristic carbons contained in the product are assigned as follows: 173.7, 173.4, 173.1, 172.8, 171.6, 171.2, 170.9, 170.8, 170.0, 169.9, 167.6, 153.5. The theoretical molecular weight of chloromethyl carbonate cyclosporin A is 1293.80, and the molecular weight actually measured by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) is 1294.80, and the molecular ion peak [M+1] belonging to chloromethyl carbonate cyclosporin A + , such as Figure 4 shown.
[0159] 1.1.2 Synthesis of iodomethyl carbonate cyclosporine A (CsA-I)
[0160] Under nitrogen protection, chloromethyl carbonate cyclosporin A (500 mg) was placed in a dry 25 mL round-bottom flask, 1 mL of anhydrous dichloromethane was added and stirred to dissolve, dichloromethane was removed by reduced pressure distillation under nitrogen flow, 5 mL of anhydrous acetonitrile was added to dissolve, sodium iodide (500 mL) was added to the reaction solution, and the reaction was carried out at 40° C. for 24 h. After the reaction was completed, acetonitrile was removed by reduced pressure distillation, and then 50 mL of anhydrous dichloromethane was added, and the mixture was washed twice with 50 mL of saturated sodium chloride solution. The organic phase was collected and then dried over anhydrous sodium sulfate. The solvent was removed by reduced pressure distillation and then vacuum dried in a vacuum drying oven (40° C.) to obtain iodomethyl carbonate cyclosporin A, which was directly used in the next step reaction.
[0161] 1.1.3 Synthesis of cyclosporine A linked to azidohexanoic acid carbonate (CsA-N3)
[0162] Under nitrogen protection, the prepared iodomethyl carbonate cyclosporin A (200 mg) was placed in a 10 mL round-bottom flask, 1 mL of anhydrous N, N-dimethylformamide (DMF) was added and stirred to dissolve, 40 mg of 6-azidohexanoic acid was dissolved in 1 mL of anhydrous DMF, and added dropwise to the iodomethyl carbonate cyclosporin A, 60 μL of anhydrous N, N-diisopropylethylamine was added, and the mixture was reacted at room temperature for 24 h. After the reaction is completed, DMF is removed by distillation under reduced pressure, 50 mL of ethyl acetate is added to dissolve, 50 mL of 10% sodium metabisulfite solution (w / v) is added to wash twice, saturated sodium chloride solution is added to wash once, and then the organic phase is collected, anhydrous sodium sulfate is added to dry, and the organic phase is filtered and concentrated by distillation under reduced pressure, and then separated and purified by silica gel column chromatography, the eluent is a mixed solution of petroleum ether / ethyl acetate (~1:2), and finally about 120 mg of a white solid product (Rf:~0.2) is collected, that is, azidohexanoic acid carbonate-modified cyclosporin A is obtained.
[0163] Cyclosporine A modified with azidohexanoic acid carbonate bond (CsA-N3) 1 HNMR spectrum Figure 5As shown, the solvent used in the NMR spectrum test was CDCl3, and the attribution of each proton peak is as follows: δ (ppm): 8.54 (1H, d), 7.98 (1H, d), 7.52 (1H, d), 7.46 (1H, d), 5.82 (1H, d), 5.70 (1H, dd), 5.68 (1H, d), 5.54 (1H, d), 5.37 (2H, m), 5. 25(2H,m),5.11(2H,m),5.06(1H,d),4.97(1H,t),4.85(1H,t),4.77(1H,t),4.66( 1H,d),4.40(1H,t),3.46(3H,s),3.31(3H,s),3.28(2H,d),3.23(3H,s),3.20(3H,s ),3.09(1H,s),2.67(3H,d),2.41(1H,t),2.12(4H,m),2.06(4H,m),1.99(2H,m),1 .87(3H,m),1.66(6H,m),1.60(4H,d),1.42(2H,m),1.33(3H,d),1.26(3H,d),1.20( 3H,d),1.14(1H,dq),1.05(7H,d),1.00(3H,d),0.96(3H,t),0.94(12H,m),0.91(3H,d),0.89(3H,d),0.88(3H,d),0.86(3H,d),0.82(9H,m),0.81(3H,d),0.76(3H,d). The theoretical molecular weight of cyclosporine A modified with azidohexanoic acid carbonate is 1415.89, and the actual measured molecular weight is 1416.90, which is attributed to the molecular ion peak of cyclosporine A modified with azidohexanoic acid carbonate [M+1] + ,like Figure 6 shown.
[0164] 1.2 Cyclosporine A and NFKBIZ antisense oligonucleotide covalent conjugate (CsA-ASO NFKBIZ )
[0165] The antisense oligonucleotides targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced dibenzocyclooctyne (DBCO) modification at the 3' end of the antisense oligonucleotide to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. The 3' end DBCO group modification is represented by -DBCO-3' in all the following examples, and its modified structure is shown below:
[0166]
[0167] The nucleic acid sequences used in this example are as follows:
[0168] The antisense oligonucleotide targeting the human NFKBIZ gene (DBCO-ASO NFKBIZ-h ) sequence is
[0169] Human:5'-ATCAGACAACGAATCGGGC-DBCO-3'(SEQ ID NO.1);
[0170] The antisense oligonucleotide targeting the mouse NFKBIZ gene (DBCO-ASO NFKBIZ-m ) sequence is
[0171] Mouse: 5'-AATACTGGTACATTGACGCC-DBCO-3' (SEQ ID NO. 2).
[0172] Single cyclosporine A molecule covalently modifies NFKBIZ antisense oligonucleotide to prepare covalent conjugate (CsA-ASO NFKBIZ ) was synthesized by dissolving 0.2 mg CsA-N3 (130 nmol) in 0.13 mL DMSO and adding 5 OD DBCO-ASO NFKBIZ (26nmol), and then placed at 50°C for 24h of shaking reaction. After adding 5mL of water, the excess CsA-N3 in the reaction was removed by extraction with ethyl acetate, and then the aqueous solution was concentrated and evaporated to dryness to obtain CsA-ASO NFKBIZ The successful coupling of CsA and ASO was verified by 10% denaturing polyacrylamide gel. Figure 7 As shown in the figure, it can be seen that single CsA and DBCO-ASO NFKBIZ The coupling efficiency is high, about 95%.
[0173] 1.3CsA-ASO NFKBIZ-h Cellular uptake of conjugates
[0174] Human corneal epithelial cells (HCEC) were cultured at a rate of 5×10 4 The cells / well were seeded in a 12-well plate and cultured overnight. After the culture medium was removed, 10 μM or 100 μM CsA-ASO with FITC fluorescence was added. NFKBIZ-h0.5 mL of fresh medium of the conjugate was incubated with HCEC cells for 6 h, and the plate without conjugate was used as blank control (Mock group). After the incubation, the supernatant medium was discarded, and the cells were digested with trypsin and washed 2 to 3 times with phosphate buffer solution (PBS, pH = 7.2). After the cells were collected, flow cytometric analysis was performed using a flow cytometer. The experimental results are shown in Figure 8 The results showed that CsA-ASO NFKBIZ-h The conjugate can be effectively taken up by cells, and the cells show obvious fluorescence enhancement signals after incubation. NFKBIZ-h The average fluorescence intensity of cells after incubation with the conjugate was about 10 times that after co-incubation with 10 μM, proving that CsA-ASO NFKBIZ-h The conjugate has good intracellular effect.
[0175] 1.4CsA-ASO NFKBIZ-h Regulatory effect of the conjugate on the target gene NFKBIZ
[0176] HCEC cells were cultured at a rate of 1×10 5 The cells were inoculated into 6-well plates at a density of 1.54 cells / well and cultured until adhered to the wall. Then, they were stimulated with 100 ng / mL lipopolysaccharide (LPS) overnight. After removing the supernatant, ASO NFKBIZ-h 、ASO NFKBIZ-h +Lipofectamine2000 (Lipo2000), and CsA-ASO NFKBIZ-h 1 mL of Opti-MEM medium (containing 10 μM ASO) was added, and cells without any treatment were used as blank reference (Mock). After co-incubation at 37°C for 6 hours, DMEM medium was replaced and incubation continued for 48 hours. Then the cells were collected and RNA was extracted for real-time fluorescence quantitative PCR (RT-qPCR) detection to analyze the mRNA expression level of the target gene NFKBIZ in HCEC cells. The experimental results are shown in Fig. 9 As shown in the figure, the expression level of NFKBIZ mRNA in HCEC cells after LPS stimulation is about 1.3 times that of normal cells. NFKBIZ-h It has a certain inhibitory effect on the expression of NFKBIZ mRNA in human ocular epithelial cells after LPS stimulation, but it is still about 1.25 times that of normal cells; ASO was transfected with Lipo2000 NFKBIZ-h After that, its expression level decreased to that of normal cells, and CsA-ASO was added NFKBIZ-h After co-incubation, the expression of NFKBIZ mRNA dropped to about 0.8 times of normal cells. NFKBIZ-hThe conjugate has a better knockdown ability on NFKBIZ mRNA than the unmodified ASO NFKBIZ-h .
[0177] 1.5CsA-ASO NFKBIZ-m The therapeutic effect of conjugates on dry eye disease
[0178] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, referred to as hospital-prepared CsA eye drops or CsA eye drops, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and CsA-ASO were used respectively. NFKBIZ-m (400μM CsA) was used for eye drops, 5μL was dropped into each eye, once in the morning and once in the evening. At the same time, fluorescein sodium staining and phenol red cotton thread tear secretion test were performed on the 0th, 7th, and 14th days of treatment to evaluate the treatment effect. The experimental results are as follows Fig.10 shown.
[0179] The results of sodium fluorescein staining showed that the eye scores of mice in the group treated with hospital-prepared CsA eye drops decreased on the 7th day, and after 14 days of treatment, the scores dropped from slightly above 6 points to about 5 points, and the tear test results of phenol red cotton thread increased from 1.5mm to about 3mm; CsA-ASO NFKBIZ-m The sodium fluorescein score of the mice in the treatment group dropped from the initial 5.5 points to about 3 points after 14 days, and the length of phenol red cotton thread infiltration increased from 1.8mm to about 3.2mm. NFKBIZ-m Due to the ability to better achieve the delivery of small molecule drugs and nucleic acid drugs, the two can synergistically inhibit ocular surface inflammation in dry eye mice, showing a better therapeutic effect on dry eye in mice.
[0180] Example 2. Covalent conjugates of cyclosporine A modified NFKBIZ antisense oligonucleotides (2CsA-ASO NFKBIZ ) and its assembled structure for synergistic treatment of dry eye
[0181] 2.12CsA-ASO NFKBIZ Preparation and characterization of conjugates and their self-assembled nanomicelles
[0182] The antisense oligonucleotides targeting the NFKBIZ gene used in this example were purchased from Shanghai Bioengineering Co., Ltd. We introduced two dibenzocyclooctyne (DBCO) modifications at the 3' end of the antisense oligonucleotides to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. One DBCO modification is the same as in Example 1 and is located at the 3' end of the nucleic acid sequence; the second DBCO modification is close to the 3' end and is a T base modification in the middle of the nucleic acid sequence. In all the following examples, the T base containing the middle modified DBCO is represented by the symbol / iDBCOdT / , and its structure is shown below:
[0183]
[0184] The nucleic acid sequences used in this example are as follows:
[0185] Among them, the antisense oligonucleotide targeting the human NFKBIZ gene (2DBCO-ASO NFKBIZ-h ) sequence is:
[0186] Human:5'-ATCAGACAACGAATCGGGC / iDBCOdT / TT-DBCO-3'(SEQ ID NO.3);
[0187] The antisense oligonucleotide targeting the mouse NFKBIZ gene (2DBCO-ASO NFKBIZ-m ) sequence is:
[0188] Mouse: 5'-AATACTGGTACATTGACGCC / iDBCOdT / TT-DBCO-3' (SEQ ID NO. 4).
[0189] 2CsA-ASO NFKBIZ The conjugate was synthesized by dissolving 0.4 mg of CsA-N3 (260 nmol) prepared in Example 1 in 0.13 mL of dimethyl sulfoxide (DMSO), adding 5 OD (optical density) of 2DBCO-ASO NFKBIZ (26nmol), and then placed at 50°C for 24h of shaking reaction. After adding 5mL of water, the excess CsA-N3 in the reaction was removed by extraction with ethyl acetate, and then concentrated and evaporated to dryness to obtain 2CsA-ASO NFKBIZ The conjugate molecules were then redissolved in 50 μL DMSO solution and then dropped into 500 μL PBS for self-assembly to form 2CsA-ASO NFKBIZThe nanomicelles were then dialyzed in a PBS solution to remove DMSO to obtain the final self-assembled nucleic acid nanomicelles. The successful grafting and coupling of CsA and antisense oligonucleotides and the successful assembly of nanomicelles were verified by 10% denaturing polyacrylamide gel electrophoresis and 1% agarose gel electrophoresis. Fig.11 As can be seen from the figure, CsA grafted 2DBCO-ASO NFKBIZ The efficiency is high, with a yield of more than 95%. At the same time, the 2CsA-ASO formed after assembly NFKBIZ The size of the nanomicelles is relatively uniform, showing a single band in the 1% agarose gel electrophoresis.
[0190] 2.22CsA-ASO NFKBIZ-h Regulatory effect of nanomicelles on target NFKBIZ gene
[0191] HCEC cells were cultured at a rate of 1×10 5 The cells / well were inoculated into 6-well plates and cultured until adhered to the wall. Then, they were stimulated with 100 ng / mL LPS overnight. After removing the supernatant, ASO-containing NFKBIZ-h +Lipo2000 complex and 2CsA-ASO NFKBIZ-h 1 mL of Opti-MEM medium (containing 10 μM ASO) was added to the nanomicelles and incubated at 37°C for 6 h. After that, the DMEM medium was replaced and incubated for another 48 h. The cells were collected and RNA was extracted for RT-qPCR to analyze the mRNA expression level of the target gene NFKBIZ in HCEC cells. The experimental results are shown in Fig.12 shown.
[0192] As can be seen from the figure, the expression of NFKBIZ mRNA in HCEC cells after LPS stimulation increased to about 1.4 times that of normal cells. NFKBIZ-h It can be downregulated to normal cellular levels, 2CsA-ASO NFKBIZ-h After co-incubation with nanomicelles, the expression of NFKBIZ mRNA in LPS-stimulated HCEC cells decreased to about 0.8 times that of normal cells. NFKBIZ-h Nanomicelles have a stronger knockdown ability on the expression of NFKBIZ gene.
[0193] 2.32CsA-ASO NFKBIZ-m The therapeutic effect of nano-micelles on dry eye
[0194] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, the hospital-prepared cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and 2CsA-ASO were used. NFKBIZ-m (400μM CsA) was used for eye drops, 5μL was dropped into each eye, once in the morning and once in the evening. At the same time, fluorescein sodium staining and phenol red cotton thread tear secretion test were performed on the 0th, 7th, and 14th days of treatment to evaluate the treatment effect. The experimental results are as follows Fig.13 shown.
[0195] The results of sodium fluorescein staining showed that after treatment with cyclosporine A eye drops, the eye score of mice dropped from 6 points to about 4 points, and the corresponding phenol red cotton thread tear test result increased from 1.5mm to about 3mm. NFKBIZ-m After nano-micelle treatment, the score of sodium fluorescein staining in the mouse eyes dropped from 6 points to about 3.5 points, and the length of phenol red cotton thread infiltration increased from 1.5mm to about 3.5mm. From the results of animal experiments, it can be seen that compared with the case group and the hospital-prescribed CsA eye drops treatment group, 2CsA-ASO NFKBIZ-m The therapeutic effect of nanomicelles on dry eye in mice is more obvious. First, the spherical nucleic acid nanomicelles formed by self-assembly have better cell entry ability. Second, small molecule drugs and nucleic acid drugs can achieve synergistic treatment, thereby better inhibiting inflammation of mouse eye tissue and achieving the purpose of dry eye treatment.
[0196] Example 3. Cyclosporine A modified NFKBIZ antisense oligonucleotide covalent conjugate (3CsA-ASO NFKBIZ ) and its assembly structure for synergistic treatment of dry eye disease
[0197] 3.13CsA-ASO NFKBIZ Preparation and characterization of conjugates and their self-assembled nanomicelles
[0198] The antisense oligonucleotides targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced three dibenzocyclooctyne (DBCO) modifications at the 3' end of the antisense oligonucleotides to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. One DBCO modification was located at the 3' end of the nucleic acid sequence; the other two were DBCO modifications of the T base in the middle of the nucleic acid sequence, close to the 3' end, and their sequences are as follows:
[0199] Antisense oligonucleotide targeting human NFKBIZ gene (3DBCO-ASO NFKBIZ-h ) sequence is:
[0200] Human:5'-ATCAGACAACGAATCGGGC / iDBCOdT / T / iDBCOdT / TT-DBCO-3'(SEQ IDNO.5);
[0201] Antisense oligonucleotide targeting mouse NFKBIZ gene (3DBCO-ASO NFKBIZ-m ) sequence is:
[0202] Mouse:5'-AATACTGGTACATTGACGCC / iDBCOdT / T / iDBCOdT / TT-DBCO-3' (SEQ ID NO. 6).
[0203] 3CsA-ASO NFKBIZ The conjugate synthesis method is as follows: 0.6 mg CsA-N3 (390 nmol) is dissolved in 0.13 mL DMSO, 5 OD DNA (26 nmol) is added, and the mixture is placed at 50°C for 24 h of shaking reaction. After adding 5 mL of water, the excess CsA-N3 in the reaction is removed by extraction with ethyl acetate, and 3CsA-ASO is obtained after concentration and evaporation. NFKBIZ The conjugate molecules were then redissolved in 50 μL DMSO solution, and the resulting solution was dropped into 500 μL PBS to assemble into 3CsA-ASO. NFKBIZ Nanomicelles were then dialyzed in PBS solution to remove DMSO to obtain the final nanomicelle assembly structure. The successful grafting and assembly were verified by 10% denaturing polyacrylamide gel electrophoresis and 1% agarose gel electrophoresis. Fig.14 As can be seen from the figure, CsA grafted 3DBCO-ASO NFKBIZ The efficiency is higher and the size after assembly is more uniform.
[0204] 3.2 3CsA-ASO NFKBIZ-h Regulatory effect of nanomicelles on NFKBIZ gene
[0205] HCEC cells were cultured at a rate of 1×10 5 The cells were seeded at a density of 1000 μg / mL in a 6-well plate and incubated until adhered to the wall. They were stimulated with 100 ng / mL LPS overnight, the supernatant was removed, and ASO-containing NFKBIZ-h +Lipo2000 complex and 3CsA-ASO NFKBIZ-h1 mL of Opti-MEM medium (containing 10 μM ASO) was added to the nanomicelles and incubated at 37°C for 6 h. After transfection, the cells were replaced with DMEM medium and incubated for 48 h. The cells were then collected and RNA was extracted for RT-qPCR testing to evaluate the expression of NFKBIZ mRNA in HCEC cells. The experimental results are shown in Fig.15 shown.
[0206] As can be seen from the figure, the expression of NFKBIZ mRNA in HCEC cells after LPS stimulation increased to about 1.4 times that of normal cells. NFKBIZ-h It can be downregulated to normal cellular levels, 3CsA-ASO NFKBIZ-h Nano-micelles down-regulated the NFKBIZ gene to about 0.75 times of normal cells. Therefore, compared with single ASO, 3CsA-ASO NFKBIZ-h Nanomicelles have a better ability to downregulate the expression of NFKBIZ gene.
[0207] 3.3 3CsA-ASO NFKBIZ-m The therapeutic effect of nano-micelles on dry eye
[0208] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and 3CsA-ASO were used respectively. NFKBIZ-m Nano-micelles (133 μM ASO concentration, 400 μM CsA) were used for eye drops, 5 μL per eye, once in the morning and once in the evening. At the same time, sodium fluorescein staining and phenol red cotton thread were used to evaluate the treatment effect on the 0th, 7th, and 14th days of treatment. The experimental results are as follows Fig.16 shown.
[0209] The results of sodium fluorescein staining showed that the eye score of mice treated with cyclosporine A eye drops dropped from 10 points to about 8 points, and the tear test result of phenol red cotton thread increased from 1mm to about 2.5mm; 3CsA-ASO NFKBIZ-m After the nano-micelle treatment, the sodium fluorescein score of the mouse eyes dropped from 10 points to about 4 points, and the length of phenol red cotton thread infiltration increased from 1.3mm to about 4mm. From the results of animal experiments, it can be seen that compared with the case group and the simple CsA eye drops group, the nano-micelles assembled after the three CsAs were coupled with the ASO targeting NFKBIZ had a more obvious therapeutic effect on dry eye in mice.
[0210] Example 4 Cyclosporine A trimer (CsA3) modified NFKBIZ antisense oligonucleotide covalent conjugate (CsA3-ASO NFKBIZ ) and its nano-micelle assembly structure for the treatment of dry eye
[0211] 4.1 Synthesis of the linker aminotris[(2-propynyloxy)methyl]methane, see Fig.17
[0212] a) Synthesis of Boc-aminotris[(2-propynyloxy)methyl]methane. 1.0 g of Boc-aminotris(hydroxymethyl)methane (4.52 mmol, 1 equivalent) was dissolved in 10 mL of anhydrous N,N-dimethylformamide (DMF). The mixture was stirred in an ice bath, and 3.2 g of bromopropyne (27.12 mmol, 6 equivalents) was added. Then, 1.5 g of potassium hydroxide powder (27.12 mmol, 6 equivalents) was added to the mixture in 3 batches within 15 min, the reaction temperature was raised to 35° C., and the reaction was continued for 24 h under a nitrogen atmosphere. After 100 mL of ethyl acetate was added to the reaction solution, it was washed with 200 mL of deionized water 3 times. The organic phase of ethyl acetate was extracted and collected, anhydrous sodium sulfate was added to remove water, and then evaporated to dryness. The product was purified by silica gel column chromatography to obtain Boc-aminotris[(2-propynyloxy)methyl]methane. The eluent was a mixed solution of n-hexane / ethyl acetate. The yield of Boc-aminotri(propargyl)methane was 64%. The NMR spectrum of the product and the peak attribution are shown in Fig.18 .
[0213] b) Synthesis of aminotri[(2-propynyloxy)methyl]methane. 0.5g of Boc-aminotri[(2-propynyloxy)methyl]methane was dissolved in 5mL of anhydrous dichloromethane. The mixed solution was then placed in an ice-water bath and stirred, and 3mL of trifluoroacetic acid (TFA) was slowly added dropwise to the mixed solution and continued to stir for about 2h. After the reaction was completed, the solvent was evaporated to dryness using a rotary evaporator, and then 15mL of saturated sodium bicarbonate solution was added, and 50mL of ethyl acetate was added for extraction 3 times. The organic layer was collected and combined and washed with 15mL of deionized water, and then the organic phase was collected again and anhydrous sodium sulfate was added to remove water and the solvent was evaporated to dryness by rotary evaporation, and aminotri[(2-propynyloxy)methyl]methane was finally obtained with a yield of 98%.
[0214] 4.2 Synthesis of cyclosporine A trimer-ASO conjugate (CsA3-ASO), steps are shown in Fig.19
[0215] The antisense oligonucleotides targeting the NFKBIZ gene used in this example were purchased from Shanghai Bioengineering Co., Ltd. We introduced an N-hydroxysuccinimide ester (NHS ester) functional group at the 3' end of the antisense oligonucleotide, which enabled it to undergo a coupling reaction with aminotri[(2-propynyloxy)methyl]methane to obtain an antisense oligonucleotide with three alkynyl groups at the 3' end, which was then efficiently coupled with the azide group modified on CsA-N3 through a click reaction. The 3' end NHS group modification is represented by -NHS-3' in all the following examples, and its modified structure is shown below:
[0216]
[0217] The nucleic acid sequences used in this example are as follows:
[0218] Antisense oligonucleotides targeting human NFKBIZ gene (NHS-ASO NFKBIZ-h ) sequence is:
[0219] Human:5'-ATCAGACAACGAATCGGGC-NHS-3' (SEQ ID NO.7);
[0220] Antisense oligonucleotides targeting the mouse NFKBIZ gene (NHS-ASO NFKBIZ-m ) sequence is:
[0221] Mouse: 5'-AATACTGGTACATTGACGCC-NHS-3' (SEQ ID NO. 8).
[0222] The synthesis method of CsA3-ASO conjugate is:
[0223] a) Dissolve 1.20 mg of aminotri[(2-propynyloxy)methyl]methane (5.12 μmol, 50 equivalents) in 800 μL DMSO, and 20 OD of hydroxysuccinimide-modified antisense oligonucleotide (NHS-ASO, 102.40 nmol, 1 equivalent) in 200 μL 1×PBS buffer solution. Mix the two phases thoroughly according to the volume ratio of DMSO to 1×PBS buffer solution of 4:1, and stir overnight at room temperature. After adding deionized water, extract with ethyl acetate to remove the excess aminotri[(2-propynyloxy)methyl]methane in the reaction, and concentrate and evaporate to dryness to obtain the tripropargyl-modified ASO conjugate molecule. In 1×TBE buffer solution, run at 600 V for 2 hours, and verify the successful grafting of the conjugate molecule by 20% denaturing polyacrylamide gel electrophoresis, see Fig. 20 .
[0224] b) 1.09 mg of azidohexanoic acid carbonate-linked cyclosporine A (CsA-N3, 0.77 μmol, 15 equivalents) and 0.56 mg of CuI·TBTA (0.77 μmol, 15 equivalents) were dissolved in 475 μL DMF, and 10 OD of tripropargyl-modified ASO conjugate molecules (51.20 nmol, 1 equivalent) were dissolved in 25 μL of sterile water. The two phases were fully mixed according to a DMF to water volume ratio of 95:5, and the reaction was stirred overnight under nitrogen protection. Then, the mixture was concentrated in vacuo to a trace volume and purified by high performance liquid chromatography (HPLC) to obtain cyclosporine A trimer-ASO conjugate (CsA3-ASO NFKBIZ ). The successful grafting was verified by 0.5% agarose gel electrophoresis in 1×TAE buffer solution at 80V for 20 min. Fig.21 .
[0225] 4.3 CsA3-ASO NFKBIZ Preparation and characterization of nanomicelles
[0226] CsA3-ASO NFKBIZ The conjugate (10ODASO) was dissolved in 100μL DMSO and added dropwise to 300μL of 1×PBS buffer solution with continuous stirring. The solution was then placed in a dialysis bag and dialyzed overnight to remove DMSO. After centrifugation at 3000 rpm for 5 minutes, CsA3-ASO was obtained. NFKBIZ Micellar nanoparticles. Their diameter and morphology were characterized by DLS and TEM, such as Fig. 22 shown.
[0227] 4.4CsA3-ASO NFKBIZ-h Regulatory effect of nanomicelles on NFKBIZ gene
[0228] HCEC cells were cultured at a rate of 1×10 5 Cells were seeded in 6-well plates at a density of 1.54 × 10 / well and incubated until adhered to the wall. They were stimulated with 100 ng / mL PPS overnight and ASO-containing NFKBIZ-h +Lipo2000 complex and CsA3-ASO NFKBIZ-h 1 mL of Opti-MEM medium (containing 10 μM ASO) was added to the nanomicelles and incubated at 37°C for 6 h. After that, the DMEM medium was replaced and incubated for 48 h. The cells were then collected and RNA was extracted for RT-qPCR to evaluate the expression of NFKBIZ mRNA in HCEC cells. The experimental results are shown in Fig.23 shown.
[0229] As can be seen from the figure, the expression level of NFKBIZ mRNA in HCEC cells after LPS stimulation is about 1.5 times that of normal cells. After ASO transfection with Lipo2000, the content of NFKBIZ mRNA decreased to the expression level of normal cells. NFKBIZ-h After the nano-micelles were added, the mRNA expression of NFKBIZ was reduced to about 0.5 times of that of normal cells. NFKBIZ-h Nanomicelles have a significant downregulation ability on NFKBIZ mRNA.
[0230] 4.5CsA3-ASO NFKBIZ-m Nano-micelles for the treatment of dry eye
[0231] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and CsA3-ASO were used respectively. NFKBIZ-m Nano-micelles (400 μM CsA) were used for eye drops, 5 μL per eye, once in the morning and evening. At the same time, sodium fluorescein staining and phenol red cotton thread were used to evaluate the treatment effect on the 0th and 14th days of treatment. The experimental results are as follows Fig.24 shown.
[0232] The results of sodium fluorescein staining showed that the eye score of mice treated with cyclosporine A eye drops dropped to about 7.5 points out of 10, and the tear test result of phenol red cotton thread increased from 1.5mm to about 2mm; CsA3-ASO NFKBIZ-m After the nano-micelle treatment, the sodium fluorescein score of the mouse eyes dropped from 10 points to about 6 points, and the length of phenol red cotton thread infiltration increased from 1.5mm to about 3.5mm. From the results of animal experiments, it can be seen that compared with the case group and the simple CsA eye drops group, the nano-micelles assembled after the three CsAs were coupled with the ASO targeting NFKBIZ had a more obvious therapeutic effect on dry eye in mice.
[0233] Example 5. Single, double, and triple cyclosporine A molecules conjugates with small interfering RNA targeting NFKBIZ (nCsA-siRNA NFKBIZ , n = 1, 2, or 3) for the synergistic treatment of dry eye disease
[0234] 5.1 Single, double, and triple CsA and siRNA NFKBIZ Conjugate (nCsA-siRNA NFKBIZ, n = 1, 2, or 3) preparation and characterization
[0235] The small interfering RNAs targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced n (n=1, 2, or 3) dibenzocyclooctyne (DBCO) modifications at the 3' end of the sense strand of the small interfering RNA to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. The specific sequence information of the siRNA selected in this example is listed in detail below.
[0236] The siRNA sequences that modify 1, 2, and 3 DBCOs and target the human NFKBIZ gene are as follows:
[0237] DBCO-siRNA NFKBIZ-h
[0238] Sense 5'-rGrCrCrCrGrArUrUrCrGrUrUrGrUrCrUrGrArUdTdT-DBCO-3' (SEQ IDNO.9);
[0239] Antisense 5'-rArUrCrArGrArCrArArCrGrArArUrCrGrGrGrCdTdT-3' (SEQ ID NO. 10);
[0240] 2DBCO-siRNA NFKBIZ-h
[0241] Sense 5'-rGrCrCrCrGrArUrUrCrGrUrUrGrUrCrUrGrArUdTdT / iDBCOdT / dTdT-DBCO-3' (SEQ ID NO. 11);
[0242] Antisense 5'-rArUrCrArGrArCrArArCrGrArArUrCrGrGrGrCdTdT-3' (SEQ ID NO. 12);
[0243] 3DBCO-siRNA NFKBIZ-h
[0244] Sense5'-rGrCrCrCrGrArUrUrCrGrUrUrGrUrCrUrGrArUdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3(SEQ ID NO.13)
[0245] Antisense 5’-rArUrCrArGrArCrArArCrGrArArUrCrGrGrGrCdTdT-3’(SEQ ID NO.14).
[0246] The murine NFKBIZ siRNA sequences modified with 1, 2, and 3 DBCOs are as follows:
[0247] DBCO-siRNA NFKBIZ-m
[0248] Sense 5’-rGrCrGrUrCrArArUrGrUrArCrCrArGrUrArUrUdTdT-DBCO-3’(SEQ ID NO.15)
[0249] Antisense 5’-rArArUrArCrUrGrGrUrArCrArUrUrGrArCrGrCdCdT-3’(SEQ ID NO.16)
[0250] 2DBCO-siRNA NFKBIZ-m
[0251] Sense 5’-rGrCrGrUrCrArArUrGrUrArCrCrArGrUrArUrUdTdT / iDBCOdT / dTdT-DBCO-3’(SEQ ID NO.17)
[0252] Antisense 5’-rArArUrArCrUrGrGrUrArCrArUrUrGrArCrGrCdCdT-3’(SEQ ID NO.18)
[0253] 3DBCO-siRNA NFKBIZ-m
[0254] Sense5’-rGrCrGrUrCrArArUrGrUrArCrCrArGrUrArUrUdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3’
[0255] (SEQ ID NO.19)
[0256] Antisense 5’-rArArUrArCrUrGrGrUrArCrArUrUrGrArCrGrCrCdT-3’(SEQ ID NO.20)
[0257] The synthesis method of cyclosporine A and siRNA conjugates is as follows: 0.2 mg, 0.4 mg, and 0.6 mg of CsA-N3 (140 nmol, 280 nmol, and 420 nmol) are dissolved in 0.14 mL of DMSO, and 5 OD of DBCO-siRNA is added respectively. NFKBIZ Sense chain, 2DBCO-siRNA NFKBIZ Sense strand, 3DBCO-siRNA NFKBIZ Sense chain (28 nmol each) was added and placed at 37°C for 24 h of shaking reaction. After adding 5 mL of water, the excess CsA-N3 in the reaction was removed by extraction with ethyl acetate, and CsA-siRNA was obtained after concentration and evaporation. NFKBIZ Sense chain, 2CsA-siRNA NFKBIZ Sense chain, 3CsA-siRNA NFKBIZ Sense chain conjugate molecule. The prepared CsA-siRNA NFKBIZ Sense chain and equivalent mass of siRNA NFKBIZ The Antisense chain is mixed in 1×PBS, and the Sense chain and Antisense chain complement each other to form soluble CsA-siRNA NFKBIZ Conjugate double-stranded molecule. For CsA-siRNA modified with two or three CsAs NFKBIZ Sense chain, first 2CsA-siRNA NFKBIZ Sense chain, 3CsA-siRNA NFKBIZ The sense chain was redissolved in 50 μL DMSO and then dropped into 500 μL 1× PBS buffer solution for assembly. DMSO was removed by dialysis in 1× PBS to obtain 2CsA-siRNA. NFKBIZ Sense chain nanomicelles, 3CsA-siRNA NFKBIZ Sense chain nanomicelles, and finally complementarily paired with the added Antisense chain to form 2CsA-siRNA NFKBIZ , and 2CsA-siRNA NFKBIZ Nano-micelles. The obtained products were characterized by polyacrylamide gel electrophoresis and agarose gel electrophoresis. Fig.25 As shown in the figure, CsA-N3 successfully interacted with siRNA NFKBIZ The Sense chain is coupled without affecting the subsequent complementary pairing and assembly with the corresponding Antisense chain.
[0258] 5.2nCsA-siRNA NFKBIZ-h (n=1,2,3) and its assembly structure regulate IκB-ζ protein
[0259] nCsA-siRNA NFKBIZ-h (n=1,2,3) Nano-micelles are designed to reduce the NFKBIZ mRNA level in cells, thereby further reducing the expression at the protein level. In order to examine the expression level of IκB-ζ protein in HCEC cells and the down-regulation effect of different drugs on it, western blot experiments were performed for characterization. HCEC cells were cultured at 1×10 5 The cells were seeded at a density of 100 μg / well in a 6-well plate and allowed to adhere overnight. After stimulating with 100 ng / mL LPS overnight, the supernatant was removed and the cells were added with siRNA. NFKBIZ-h +Lipo2000 complex and nCsA-siRNA NFKBIZ-h (n=1, 2, 3) 1 mL of Opti-MEM medium (both containing 10 μM siRNA) for the conjugates and nanomicelles was co-incubated at 37°C for 6 h before transfection and then changed to DMEM medium. After further incubation for 48 h, the proteins in the cells were extracted and western blot experiments were performed.
[0260] The experimental results are as follows Fig.26 As shown in the data, the expression level of IκB-ζ protein in HCEC cells after LPS stimulation is about 1.5 times that of normal cells. NFKBIZ-h The expression level of IκB-ζ protein in the cells was about 1.2 times that of normal cells. NFKBIZ-h Conjugate, 2CsA-siRNA NFKBIZ Nanomicelles and 3CsA-siRNA NFKBIZ After the nano-micelles were added, the expression of IκB-ζ protein was reduced to about 0.5-0.8 times of normal cells. NFKBIZ-h It can effectively reduce the expression of IκB-ζ protein caused by inflammation after LPS stimulation, and the effect of reducing IκB-ζ protein is better as the number of CsA modifications increases; at the same time, nCsA-siRNA NFKBIZ-h (n=1,2,3) The effects of conjugates and nanomicelles are better than Lipo2000 in transfecting siRNA NFKBIZ-h Group.
[0261] 5.3nCsA-siRNA NFKBIZ-h (n=1,2,3) and its assembled structure's regulatory effect on NFKBIZ gene
[0262] HCEC cells were cultured at a rate of 1×10 5The cells were seeded at a density of 1.54 × 10 / well in a 6-well plate and allowed to adhere overnight. Then, they were stimulated with 100 ng / mL LPS for 12 h. After the supernatant was removed, siRNA-containing NFKBIZ-h +Lipo2000 complex and nCsA-siRNA NFKBIZ-h (n=1, 2, 3) 1 mL of Opti-MEM medium (all containing 10 μM siRNA) for the conjugate and nanomicelles was co-incubated at 37°C for 6 h before being switched to DMEM medium. After a further 48 h of incubation, the cells were collected and RNA was extracted for RT-qPCR experiments to evaluate the expression of NFKBIZ mRNA in HCEC cells. The experimental results are shown in Fig. 27 shown.
[0263] It can be seen from the data that compared with the blank group (Mock group), CsA-siRNA NFKBIZ-h The expression of NFKBIZ gene was significantly reduced to the level before LPS stimulation; at the same time, the expression of NFKBIZ in HCEC cells after LPS stimulation increased to about 1.5 times that of normal cells. NFKBIZ-h As the number of CsA modifications increased, its effect on reducing the NFKBIZ gene increased, reducing the expression of NFKBIZ in cells to about 0.5 to 0.7 times that of normal cells. This may be due to the hydrophobic effect of CsA enhancing the siRNA NFKBIZ-h The synergistic effect of the two has better ability to treat inflammation.
[0264] 5.4nCsA-siRNA NFKBIZ-m (n=1,2,3) and its assembled structure for the treatment of dry eye
[0265] The ocular dry eye model was established in 6-8 week old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) using 0.2% benzalkonium chloride. 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mice, once in the morning and once in the evening every day, for two weeks. After the model was successfully established, the hospital-prepared cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and CsA-siRNA were used respectively. NFKBIZ-m (400 μM CsA), 2CsA-siRNA NFKBIZ-m Nanomicelles (400 μM CsA), 3CsA-siRNA NFKBIZ-m Nano-micelles (400 μM CsA) were used for eye drops, 5 μL per eye, once in the morning and once in the evening. Fluorescein sodium staining and phenol red cotton thread were used to evaluate the therapeutic effect on the 0th, 7th, and 14th days of treatment. The experimental results are as follows Fig.28shown.
[0266] The results of sodium fluorescein staining showed that the eye score of mice treated with cyclosporine A eye drops dropped from 6 points to about 4.5 points, and the tear test result of phenol red cotton thread increased from 1.5mm to about 2.5mm; CsA-siRNA NFKBIZ After treatment, the eye score of mice dropped from 6 points to about 3 points, and the tear test result of phenol red cotton thread increased from 2mm to about 2.5mm; 2CsA-siRNA NFKBIZ After the treatment with nano-micelles, the eye score of mice dropped from 6 points to about 2 points, and the tear test result of phenol red cotton thread increased from 1.5mm to about 2.5mm; 3CsA-siRNA NFKBIZ The eye score of mice treated with nano-micelles dropped from 6 points to about 2 points, and the tear test result of phenol red cotton thread increased from 1.5mm to about 2.5mm. It can be seen from the animal experimental results that compared with the case group and the simple CsA eye drops group, CsA-siRNA NFKBIZ-m Conjugate, 2CsA-siRNA NFKBIZ-m Nanomicelles, 3CsA-siRNA NFKBIZ-m The therapeutic effect of nano-micelles on dry eye in mice is more obvious. Firstly, the synergistic treatment of small molecule drugs and nucleic acid drugs can better inhibit the inflammation of mouse eye cells. Secondly, the hydrophobic CsA gives siRNA better cell entry ability.
[0267] Example 6 Multiple Cyclosporine A Molecules Grafted with NFKBIZ Antisense Oligonucleotide Conjugates and Their Self-Assembled Nanomicelles for the Treatment of Dry Eye Disease
[0268] 6.1 Synthesis and Characterization of Carboethyl Cyclosporine A Bromide (CsA-Br)
[0269] like Fig.29 As shown, first, CsA (100 mg) and triphosgene (9 mg) were placed in a flask, and the air was evacuated three times, and then 16 mL of dichloromethane was added under nitrogen protection to dissolve, and then DMAP (31 mg) was dissolved in 1 mL of dichloromethane and added dropwise to the reaction solution, and reacted at room temperature for 30 minutes, and the phenomenon was that the solution turned milky white, and then butanediol (72 mg) was dissolved in 1 mL of dichloromethane and added dropwise to the reaction solution, and reacted at room temperature overnight, and the phenomenon was that the solution changed from milky white to colorless and transparent. After the reaction was completed, according to the amount of DMAP, it was washed three times with dilute hydrochloric acid solution, washed once with saturated sodium chloride solution, and dried with anhydrous sodium sulfate powder for more than 2 hours. After the organic phase was concentrated by vacuum distillation, it was separated and purified by silica gel column chromatography, and the eluent was a petroleum ether / ethyl acetate mixed solution, and a white solid was obtained, that is, the cyclosporin A molecule modified with butanediol.
[0270] CsA-butanediol (90 mg) and DIPEA (8 mg) were placed in a flask, and the air was evacuated three times, and then 16 mL of dichloromethane was added under nitrogen protection. Then, bromoacetyl bromide (16 mg) was dissolved in 1 mL of dichloromethane and added dropwise to the reaction solution, and the reaction was allowed to react overnight at room temperature. After the reaction, the mixture was washed three times with dilute hydrochloric acid solution and once with saturated sodium chloride solution according to the amount of DIPEA, and dried with anhydrous sodium sulfate powder for more than 2 hours. The organic phase was concentrated by vacuum distillation and then separated and purified by silica gel column chromatography, and the eluent was a petroleum ether / ethyl acetate mixed solution, and finally a yellow solid was obtained, namely, carbonylethyl bromide cyclosporin A was obtained. 1 HNMR(700MHz,Chloroform-d)δ7.99(d,J=9.7Hz,1H),7.64(d,J=7.5Hz,1H),7.47(d,J=8.3Hz,1H),7.41(s,1H),7. 28(s,1H),7.16(d,J=7.9Hz,2H),7.11(s,1H),5.70(d,J=6.6Hz,1H),5.48(d,J=6.3Hz,1H),5.36–5.32(m,3H),5.12 (d,J=10.9Hz,1H),5.08–5.02(m,3H),4.97(dd,J=9.9,5.9Hz,1H),4.85–4.81(m,2H),4.72(d,J=13.9Hz,1H),4.65( dd,J=9.9,8.4Hz,2H),4.52(t,J=7.3Hz,2H),3.80(t,J=6.5Hz,2H),3.51(s,3H),3.40(s,3H),3.26(s,3H),3.20(s, 1H),3.18(s,1H),3.11(d,J=1.6Hz,5H),2.96(s,1H),2.89(s,1H),2.69(d,J=5.8Hz,6H),2.41(dd,J=12.1,7.7Hz, 2H),2.13(d,J=11.1Hz,2H),2.08–2.05(m,2H),1.99(s,1H),1.77(s,2H),1.73–1.69(m,2H),1.63(d,J=7.4Hz,4H), 1.58(s,6H),1.47(d,J=6.5Hz,1H),1.43(s,1H),1.35(d,J=7.3Hz,3H),1.25(d,J=6.7Hz,6H),1.07(d,J=6.5Hz,2H) ,1.02(dd,J=14.8,6.6Hz,7H),0.97–0.93(m,8H),0.89–0.84(m,13H),0.83(d,J=6.6Hz,3H),0.71(d,J=6.1Hz,3H).
[0271] The theoretical m / z values of carbonylethyl bromide cyclosporine A are 1437.8098 and 1439.8077 due to the presence of isotopic ion peaks of bromine element. The m / z values measured by HPLC / quadrupole flight mass spectrometry are 1438.4549 and 1440.4506, which belong to the [M+H]+ peak of carbonylethyl bromide cyclosporine A, confirming that the target product was successfully synthesized. Fig.30 shown.
[0272] 6.220CsA-ASO NFKBIZ Conjugates and 20CsA-ASO NFKBIZ Preparation and characterization of nanomicelles
[0273] The antisense oligonucleotides targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We chose to perform thio (PS) modification in the antisense nucleotide phosphate backbone so that it can undergo a substitution reaction with the bromocarbonylethyl group modified on CsA-Br for efficient coupling. The sequence is as follows:
[0274] Antisense oligonucleotide targeting human NFKBIZ gene (20PS-ASO NFKBIZ-h ) sequence is:
[0275] 5'-ATCAGACAACGAATCGGGC TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(wherein * represents a phosphorothioate group modification site, indicating that the two nucleotide units before and after are connected by a phosphorothioate group. In the following examples, phosphorothioate modifications in the nucleic acid sequences are represented by * unless otherwise specified, and underscores are used. TTTTT To connect the 5' end ASO and the 3' end multiple T base spacer sequences for drug modification sequences, the underlined parts of the sequences listed in the following embodiments all represent the spacer sequences connecting the functional small nucleic acid sequence and the drug modification sequence, which will not be repeated one by one) (SEQ ID NO.21);
[0276] Among them, the antisense oligonucleotide targeting the mouse NFKBIZ gene (20PS-ASO NFKBIZ-m ) sequence is:
[0277] 5'-AATACTGGTACATTGACGCC TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3' (SEQ ID NO. 22);
[0278] The synthesis method is as follows: 7.5 mg CsA-Br (5 μmol) was dissolved in 0.063 mL DMSO, and 5 OD20 PS-ASO was added. NFKBIZ (12.5 nmol) and placed at 50°C for 24 h of shaking reaction. After adding 5 mL of water, the excess CsA-Br in the reaction was removed by extraction with ethyl acetate, and then concentrated and evaporated to dryness to obtain 20CsA-ASO NFKBIZ Conjugate molecule. 20CsA-ASO NFKBIZ The conjugate was dissolved in 50 μL DMSO, added dropwise to 0.5 mL phosphate buffer (PBS), and stirred for 30 min. It was then placed in a dialysis bag and dialyzed in PBS overnight to remove DMSO to obtain 20CsA-ASO. NFKBIZ Nanomicelle structure was characterized by 10% denaturing polyacrylamide gel electrophoresis and 1% agarose gel electrophoresis. Fig.31 As can be seen, CsA-Br was successfully grafted onto 20PS-ASO NFKBIZ , and formed a 20PS-ASO with relatively uniform size NFKBIZ Nanomicelle assemblies.
[0279] 6.320CsA-ASO NFKBIZ-h Knockdown of NFKBIZ gene by nanomicelles
[0280] HCEC cells were cultured at a rate of 1×10 5 The cells were plated at a density of 100 ng / mL and adhered to the wall of a 6-well plate. They were then stimulated with 100 ng / mL LPS for 12 h. The supernatant was removed and ASO was added to the plates. NFKBIZ-h +Lipofectamine2000 (Lipo2000) and 20CsA-ASO NFKBIZ-h 1 mL of Opti-MEM medium (containing 10 μM ASO) was added to the nanomicelles and co-incubated for 6 h at 37 °C, then changed to DMEM medium. After changing to the new medium, the cells were incubated for 48 h. The cells were then collected and RNA was extracted for RT-qPCR experiments to examine the expression level of NFKBIZ mRNA in HCEC cells. The experimental results are shown in Fig.32 shown.
[0281] As can be seen from the figure, the expression of NFKBIZ mRNA in HCEC cells after LPS stimulation increased to about 1.5 times that of normal cells. NFKBIZ-h It can be downregulated to the level of normal cells, 20CsA-ASO NFKBIZ-h Nano-micelles down-regulated the NFKBIZ gene to about 0.75 times the normal cell expression level, so compared with a single ASO NFKBIZ-h , 20CsA-ASONFKBIZ-h Nanomicelles have a better ability to downregulate the expression of NFKBIZ gene.
[0282] 6.420CsA-ASO NFKBIZ-m The therapeutic effect of nano-micelles on dry eye
[0283] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine) and 20CsA-ASO were used respectively. NFKBIZ-m Nano-micelles (20 μM, 400 μM CsA) were used for eye drops, 5 μL per eye, once in the morning and evening. At the same time, sodium fluorescein staining and phenol red cotton thread were used to evaluate the treatment effect on the 0th and 14th day of treatment. The experimental results are shown in the figure. Fig.33 shown.
[0284] From the results of animal experiments, it can be seen that the results of sodium fluorescein staining showed that the eye score of mice treated with cyclosporine A eye drops in the hospital increased from 9 points to about 11 points, with no significant improvement. The tear test results of phenol red cotton thread remained at about 2.5mm without significant changes; 20CsA-ASO NFKBIZ-m After the nano-micelle treatment, the fluorescein sodium score of the mice eyes dropped from 9 points to about 7.5 points, and the length of the phenol red cotton thread infiltration increased from 3mm to about 5.5mm. Therefore, it can be seen that compared with the hospital-prescribed cyclosporine A eye drops, 20CsA-ASO NFKBIZ-m Nano-micelles have a significant therapeutic effect on dry eye disease in mice.
[0285] Example 7. Covalent conjugates of cyclosporine A molecules with small interfering nucleic acids targeting IL-17, IL-1β, IL-23 and TNF-α and their self-assembled nanomicelles for the treatment of dry eye
[0286] 7.1 Preparation of CsA-siRNA Conjugates and Nanomicelles
[0287] The small interfering nucleic acids targeting different inflammatory factor genes used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced three dibenzocyclooctyne (DBCO) modifications at the 3' end of the siRNA sense strand to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. The sequence is as follows:
[0288] The siRNA sequences targeting different human inflammatory factor genes are:
[0289] IL-17human(3DBCO-siRNA IL-17-h )
[0290] Sense5’-rCrUrCrUrArArUrGrArGrUrUrUrArGrUrCrCrGrAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3’(SEQ ID NO.23)
[0291] Antisense 5’-rUrCrGrGrArCrUrArArArCrUrCrArUrUrArGrArGdTdT-3'(SEQ IDNO.24)
[0292] IL-1βhuman(3DBCO-siRNA IL-1β-h )
[0293] Sense5’-rArGrGrCrUrGrArUrCrUrGrUrUrGrCrCrGrUrAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3’(SEQ ID NO.25)
[0294] Antisense 5’-rUrArCrGrGrCrArArCrArGrArUrCrArGrCrCrUdTdG-3’(SEQ IDNO.26)
[0295] IL-23human(3DBCO-siRNA IL-23-h )
[0296] Sense5’-rCrArGrCrArArCrCrCrUrGrArGrUrCrCrCrUrAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3’(SEQ ID NO.27)
[0297] Antisense 5’-rUrArGrGrGrArCrUrCrArGrGrGrUrUrGrCrUrGdTdT-3’(SEQ IDNO.28)
[0298] TNF-αhuman(3DBCO-siRNA TNF-α-h )
[0299] Sense5′-rGrArCrArArCrArArCrUrArGrUrGrGrUrGrCdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3′ (SEQ ID NO. 29)
[0300] Antisense 5'-rGrCrArCrCrArCrUrArGrUrUrGrGrUrUrGrUrCdTdT-3'(SEQ IDNO.30)
[0301] The siRNA sequences targeting different mouse inflammatory factor genes are:
[0302] IL-17mouse(3DBCO-siRNA IL-17-m )
[0303] Sense5'-rArArGrArGrArUrCrCrUrGrGrUrCrCrUrGrArAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.31)
[0304] Antisense 5'-rUrUrCrArGrGrArCrCrArGrGrArUrCrUrCrUrUdGdC-3'(SEQ IDNO.32)
[0305] IL-1βmouse(3DBCO-siRNA IL-1β-m )
[0306] Sense5′-rGrGrArArGrGrCrArGrUrGrUrCrArCrUrCrArUdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3′ (SEQ ID NO. 33)
[0307] Antisense 5′-rArUrGrArGrUrGrArCrArCrUrGrCrUrUrCrCdTdT-3′ (SEQ IDNO.34)
[0308] IL-23mouse(3DBCO-siRNA IL-23-m )
[0309] Sense 5'-rArCrArArCrArUrCrArCrCrArCrArCrUrGrGrArUrArCrGrGdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.35)
[0310] Antisense 5'-rCrCrGrUrArUrCrCrArGrUrGrUrGrGrUrGrArUrGrGrUrUrGrUdTdT-3'(SEQ ID NO.36)
[0311] TNF-αmouse(3DBCO-siRNA TNF-α-m )
[0312] Sense5′-rGrUrCrUrCrArGrCrCrUrCrUrUrCrUrCrArUrUrCrCrUdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3′ (SEQ ID NO. 37)
[0313] Antisense 5'-rArGrGrArArUrGrArGrArArGrArGrGrCrUrGrArGrArCdTdT-3'(SEQID NO.38)
[0314] The synthesis method of 3CsA-siRNA conjugates for different targets is as follows: 30 times the molar equivalent of CsA-N3 is dissolved in DMSO, 5OD of 3DBCO-siRNA Sense chains with different targets are added to make the reaction concentration 200μM, and then placed at 37°C for 24h of shaking reaction. After adding water, the excess CsA-N3 in the reaction is removed by extraction with ethyl acetate, and 3CsA-siRNA is obtained after concentration and evaporation. IL-17 Sense chain, 3CsA-siRNA IL-1β Sense chain, 3CsA-siRNA IL-23 Sense chain and 3CsA-siRNA TNF-α Sense chain conjugate molecules. They were redissolved in 50 μL DMSO solution and then dropped into 500 μL PBS for assembly to form 3CsA-siRNA IL-17 Sense chain nanomicelles, 3CsA-siRNA IL-1β Sense chain nanomicelles, 3CsA-siRNA IL- 23 Sense chain nanomicelles and 3CsA-siRNA TNF-αSense chain nanomicelles, then dialyzed in PBS to remove DMSO. After complementary pairing with Antisense chain, 3CsA-siRNA dispersed in PBS solution was obtained. IL-17 Nanomicelles, 3CsA-siRNA IL-1β Nanomicelles, 3CsA-siRNA IL-23 Nanomicelles and 3CsA-siRNA TNF-α Nanomicelle samples.
[0315] 7.2 Regulatory effects of 3CsA-siRNA nanomicelles on targeted genes for different targets
[0316] The density is 1×10 5 HCEC cells at 100 ng / mL were placed in a 6-well plate and then stimulated with 100 ng / mL LPS for 12 h. After removing the supernatant, 1 mL of 3CsA-siRNA was added to each well. IL-17-h Nanomicelles, 3CsA-siRNA IL-1β-h Nanomicelles, 3CsA-siRNA IL-23-h Nanomicelles and 3CsA-siRNA TNF-α-h The cells were incubated at 37°C for 6 h before transfection and then replaced with DMEM medium. After 48 h of incubation, the cells were collected and RNA was extracted for PCR experiments to test the mRNA expression levels of different targets in HCEC cells. Fig.34 shown.
[0317] As can be seen from the figure, after LPS stimulation, the mRNA expression of different inflammatory factors was upregulated, about 1.2-1.4 times the expression level of each inflammatory mRNA in normal cells. After adding Lipo2000 to transfect siRNA with different targets, the expression of different inflammatory factors was reduced to between 0.8-1.1 times the normal cell level; after adding nano-micelle materials with different targets, the expression of different inflammatory factors was reduced to about 0.75 times the normal cell level. This part of the data shows that the 3CsA-siRNA nano-micelle materials with different targets have a good effect of downregulating inflammatory factor genes.
[0318] 7.3 Inhibitory effect of 3CsA-siRNA nanomicelles on the expression of related inflammatory factors targeting different targets
[0319] HCEC cells were cultured at a rate of 5 × 10 4The cells were seeded at a density of 100 ng / mL and adhered to the wall of a 12-well plate. Then, 100 ng / mL LPS was used to stimulate the plate for 12 h. After the supernatant was removed, 1 mL of 3CsA-siRNA was added to each well. IL-17-h Nanomicelles, 3CsA-siRNA IL-1β-h Nanomicelles, 3CsA-siRNA IL-23-h Nanomicelles and 3CsA-siRNA TNF-α-h The cells were co-incubated at 37°C for 6 h before transfection and then replaced with DMEM medium. After incubation for 48 h, the supernatant was collected for ELISA to detect the expression of different inflammatory factors in HCEC cells. The experimental results are shown in Table 1. Fig.35 shown.
[0320] As can be seen from the figure, after LPS stimulation, the expression of various inflammatory factors in HCEC cells increased significantly, with the increase range being about 1.5 to 2.5 times that of normal cells; after adding different target siRNAs transfected with lipo2000, the expression of inflammatory factors decreased; the expression of inflammatory factors in HCEC cells treated with various nano-micelle materials decreased the most and returned to the expression level of normal cells. This is because the drug nucleic acid conjugates assembled into nano-micelles have better cellular entry ability, and secondly, because cyclosporine A and siRNA work synergistically, a better inflammation inhibition effect is achieved.
[0321] 7.4 Therapeutic effects of 3CsA-siRNA nanomicelles on dry eye disease targeting different targets
[0322] The ocular dry eye model was constructed in 6-8 week old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) using 0.2% benzalkonium chloride. 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine), 3CsA-siRNA IL-17-m Nanomicelles, 3CsA-siRNA IL-1β-m Nanomicelles, 3CsA-siRNA IL-23-m Nanomicelles and 3CsA-siRNA TNF-α-m Nano-micelles (CsA concentration in each group of materials was 400 μM) were used for eye drops, 5 μL was dropped into each eye once a day, once in the morning and once in the evening. Fluorescein sodium staining and phenol red cotton thread were used to evaluate the therapeutic effect on the 0th and 14th days of treatment. The experimental results are shown in the figure. Fig.36 shown.
[0323] The results of sodium fluorescein staining showed that the eye score of mice in the untreated control group dropped from 13 points to about 10 points, and the phenol red cotton thread tear test results increased from 1mm to about 1.3mm, with no significant improvement; the eye score of mice treated with CsA eye drops dropped from 12 points to about 9 points, and the phenol red cotton thread tear test results increased from 1.5mm to about 3mm; the sodium fluorescein staining score of mice in the siRNA nano-micelle treatment group with different targets dropped from about 13 points to about 8 points, and the phenol red cotton thread infiltration length increased from 1.5mm to about 4mm. From these partial data results, it can be seen that the 3CsA-siRNA conjugate nano-micelles targeting different inflammatory factor targets have a certain effect on the treatment of dry eyes in mice within two weeks.
[0324] Example 8. Covalent conjugates of cyclosporine A molecules with small interfering nucleic acids targeting NLRP3, JAK1 and PDE4 and self-assembled nanomicelles thereof for the treatment of dry eye
[0325] 8.1 Preparation of CsA-siRNA Conjugates and Their Self-assembled Nanomicelles
[0326] The small interfering RNAs targeting different inflammatory genes in cells used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced three dibenzocyclooctyne (DBCO) modifications at the 3' end of the siRNA sense strand to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. The sequence is as follows:
[0327] The siRNA sequences targeting different human inflammation-related genes are:
[0328] NLRP3 human(3DBCO-siRNA NLRP3-h )
[0329] Sense5'-rGrUrGrGrArCrUrUrGrArArGrArArArUrUrUrAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.39)
[0330] Antisense 5'-rUrArArArUrUrCrUrUrCrArArGrUrCrCrArCdTdT-3'(SEQ IDNO.40)
[0331] JAK1 human(3DBCO-siRNA JAK1-h )
[0332] Sense5'-rGrGrArUrUrArCrArArGrGrArUrGrArCrGrArArGrGdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.41)
[0333] Antisense 5'-rUrUrCrGrUrCrArUrCrCrUrUrGrUrArArUrCrCrArUdTdT-3'(SEQ IDNO.42)
[0334] PDE4 human(3DBCO-siRNA PDE4-h )
[0335] Sense5'-rGrArGrUrCrGrGrUrCrUrGrGrArArArUrCrArAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.43)
[0336] Antisense 5'-rUrUrGrArUrUrUrCrArGrArCrCrGrArCrUrCdTdT-3'(SEQ IDNO.44)
[0337] The siRNA sequences targeting different inflammation-related genes of mice are:
[0338] NLRP3 mouse(3DBCO-siRNA NLRP3-m )
[0339] Sense 5'-rGrGrUrGrArArArUrGrUrArCrUrUrArArArUrCdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.45)
[0340] Antisense 5′-rGrArUrUrUrArArGrUrArCrArUrUrUrCrArCrCdTdT-3′ (SEQ IDNO.46)
[0341] JAK1 mouse (3DBCO-siRNA JAK1-m )
[0342] Sense 5'-rCrUrGrUrArUrGrGrCrGrArCrArUrUrCrUrCrArAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.47)
[0343] Antisense 5'-rUrUrGrGrArGrArArUrGrUrCrGrCrCrArUrArCrArGdTdT-3'(SEQ IDNO.48)
[0344] PDE4 mouse (3DBCO-siRNA PDE4-m )
[0345] Sense 5'-rArUrGrArGrCrGrUrGrUrArGrArGrArGrGrArCrArAdTdT / iDBCOdT / dT / iDBCOdT / dTdT-DBCO-3'(SEQ ID NO.49)
[0346] Antisense 5'-rUrUrGrUrCrCrUrCrUrCrUrArCrArCrGrCrUrCrArUdTdT-3'(SEQ IDNO.50)
[0347] The synthesis method of 3CsA-siRNA conjugates for different targets is as follows: 30 times the molar equivalent of CsA-N3 is dissolved in DMSO, 5OD of 3DBCO-siRNA Sense chains with different targets are added to make the reaction concentration 200μM, and then placed at 37°C for 24h of shaking reaction. After adding water, the excess CsA-N3 in the reaction is removed by extraction with ethyl acetate, and 3CsA-siRNA is obtained after concentration and evaporation. NLRP3 Sense chain, 3CsA-siRNA JAK1 Sense chain and 3CsA-siRNA PDE4 Sense chain conjugate molecules. They were redissolved in 50 μL DMSO solution and then dropped into 500 μL PBS to assemble into 3CsA-siRNA NLRP3 Sense chain nanomicelles, 3CsA-siRNA JAK1 Sense chain nanomicelles and 3CsA-siRNA PDE4 Sense chain nano-micelles, then dialyzed in PBS to remove DMSO. After complementary pairing with Antisense chain, 3CsA-siRNA dispersed in PBS solution was obtained. NLRP3 Nanomicelles, 3CsA-siRNA JAK1Nanomicelles and 3CsA-siRNA PDE4 Samples of nanomicelles.
[0348] 8.2 Regulatory effects of 3CsA-siRNA conjugate nanomicelles on targeted genes for different targets
[0349] The density is 1×10 5 HCEC cells at 100 ng / mL were placed in a 6-well plate and then stimulated with 100 ng / mL LPS for 12 h. After removing the supernatant, 1 mL of 3CsA-siRNA was added to each well. NLRP3-h Nanomicelles, 3CsA-siRNA JAK1-h Nanomicelles and 3CsA-siRNA PDE4-h Nanomicelles were incubated with Opti-MEM medium (all containing 10 μM siRNA), and the control group was 1 mL of Opti-MEM medium containing different target siRNA and Lipo2000 complexes (siRNA concentration was 10 μM). After co-incubation at 37°C for 6 hours, the medium was changed to DMEM medium. After incubation for 48 hours, the cells were collected and RNA was extracted for PCR experiments to examine the mRNA expression levels of different targets in HCEC cells. The experimental results are shown in Fig.37 shown.
[0350] As can be seen from the figure, after LPS stimulation, the mRNA expression of different intracellular inflammatory targets was significantly upregulated, about 1.4 times the expression level of each inflammatory mRNA in normal cells. After adding Lipo2000 to transfect siRNA with different targets, the expression of inflammatory target genes in different intracellular cells was reduced to about 1.1 times the level of normal cells; after adding nano-micelle materials with different targets, the expression of inflammatory target genes in different intracellular cells was reduced to about 0.8 times the level of normal cells. This part of the data shows that 3CsA-siRNA nano-micelle materials with different targets have a good effect of downregulating intracellular inflammatory genes.
[0351] 8.3 Therapeutic effects of 3CsA-siRNA conjugate nanomicelles on dry eye disease targeting different targets
[0352] The ocular dry eye model was constructed in 6-8 week old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) using 0.2% benzalkonium chloride. 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine), 3CsA-siRNA NLRP3-m Nanomicelles, 3CsA-siRNA JAK1-m Nanomicelles and 3CsA-siRNAPDE4-m Nano-micelles (CsA concentration in each group of materials was 400 μM) were used for eye drops, 5 μL was dropped into each eye once a day, once in the morning and once in the evening. Fluorescein sodium staining and phenol red cotton thread were used to evaluate the therapeutic effect on the 0th and 14th days of treatment. The experimental results are shown in the figure. Fig.38 shown.
[0353] The results of sodium fluorescein staining showed that the eye score of mice in the untreated control group dropped from 12 points to about 10 points, and the phenol red cotton thread tear test results were all about 1mm, with no significant improvement; the eye score of mice treated with CsA eye drops dropped from 10 points to about 8 points, and the phenol red cotton thread tear test results increased from 1mm to about 2mm; the sodium fluorescein staining score of mice in the siRNA nanomicelle material group with different targets dropped from about 10 points to about 7 points, and the phenol red cotton thread infiltration length increased from 1mm to between 3 and 4.5mm. From these partial data results, it can be seen that the drug-nucleic acid conjugate nanomicelles targeting different intracellular inflammatory targets have a significant therapeutic effect on the treatment of dry eyes in mice within two weeks.
[0354] Example 9: Cyclosporine A antisense oligonucleotide conjugate nanomicelles targeting different targets of IL-17, IL-1β, IL-23 and TNF-α for the treatment of dry eye disease
[0355] 9.1 Preparation of three cyclosporine A molecules and ASO conjugates with different targets and their self-assembled nanomicelles
[0356] The antisense oligonucleotides targeting different inflammatory factor genes used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We introduced three dibenzocyclooctyne (DBCO) modifications at the 3' end of the antisense oligonucleotides to enable efficient coupling with the azide group modified on CsA-N3 through a click reaction. The detailed sequence information of the ASO used in this example is as follows:
[0357] The antisense oligonucleotide sequences targeting different human inflammatory factor genes are:
[0358] IL-17human(3DBCO-ASO IL-17-h )
[0359] 5'-TCGGACTAAACTCATTAGAG TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3′(SEQ ID NO.51)
[0360] IL-1βhuman(3DBCO-ASO IL-1β-h )
[0361] 5′-GGTACTTCTGCCATGGCTGC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3′(SEQ ID NO.52)
[0362] IL-23human(3DBCO-ASO IL-23-h )
[0363] 5'-CATTACAGCTCTGCTCCCCAGCATC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3'(SEQ IDNO.53)
[0364] TNF-αhuman(ASO TNF-α-h )
[0365] 5'-CAGTGCTCATGGTGTC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3'(SEQ ID NO.54)
[0366] The antisense oligonucleotide sequences targeting different mouse inflammatory factor genes are:
[0367] IL-17mouse(3DBCO-ASO IL-17-m )
[0368] 5'-TTCAGGACCAGGATCTCTTGC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3′(SEQ ID NO.55)
[0369] IL-1βmouse(3DBCO-ASO IL-1β-m )
[0370] 5′-ATGAGTGACACTGCCTTCC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3′(SEQ ID NO.56)
[0371] IL-23mouse(3DBCO-ASO IL-23-m )
[0372] 5'-CCGTATCCAGTGTGGTGATGGTTGT TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3'(SEQ IDNO.57)
[0373] TNF-αmouse(3DBCO-ASOTNF-α-m )
[0374] 5'-AACCCATCGGCTGGCACCAC TT / iDBCOdT / T / iDBCOdT / TT-DBCO-3'(SEQ ID NO.58)
[0375] In this embodiment, the synthesis method of the conjugate of small molecule drugs and ASOs for different targets is as follows: 30 times the molar equivalent of CsA-N3 is dissolved in DMSO, and 5 OD of 3DBCO-ASO for different targets is added. X After that, the reaction concentration was 200 μM, and then placed at 50°C for 24 hours of shaking reaction. After adding water, the excess CsA-N3 in the reaction was removed by extraction with ethyl acetate, and after concentration and evaporation, 3CsA-ASO was obtained. IL-17 、3CsA-ASO IL-1β 、3CsA-ASO IL-23 and 3CsA-ASO TNF-α The conjugate molecules were then redissolved in 50 μL DMSO solution and dropped into 500 μL PBS to assemble into 3CsA-ASO. IL-17 Nanomicelles, 3CsA-ASO IL-1β Nanomicelles, 3CsA-ASO IL-23 Nanomicelles and 3CsA-ASO TNF-α The nanomicelles were then dialyzed in PBS to remove DMSO to obtain different nanomicelle samples dispersed in PBS solution.
[0376] 9.2 Knockdown effect of nanomicelles on corresponding genes for different targets
[0377] 1×10 5 HCEC cells at 100 ng / mL were placed in a 6-well plate and allowed to adhere to the wall. They were then stimulated with 100 ng / mL LPS for 12 h. The supernatant was removed and 1 mL of 3CsA-ASO was added to each well. IL-17-h Nanomicelles, 3CsA-ASO IL-1β-h Nanomicelles, 3CsA-ASO IL-23-h Nanomicelles and 3CsA-ASO TNF-α-h The Opti-MEM medium containing nanomicelles (all containing 10 μM ASO) and the control group were 1 mL of Opti-MEM medium containing different target ASO and Lipo2000 complexes (ASO concentration was 10 μM). After co-incubation at 37°C for 6 hours, the medium was changed to DMEM medium and continued to be incubated at 37°C for 48 hours. After that, the cells were collected and RNA was extracted for RT-qPCR detection to examine the mRNA expression levels of different targets in HCEC cells. The experimental results are shown in Fig.39shown.
[0378] As can be seen from the figure, after LPS stimulation, the mRNA expression of different inflammatory factors was upregulated, which was about 1.3-1.5 times that of normal cells. After adding different target ASOs transfected with Lipo2000, the expression of different inflammatory factors was reduced to between 0.8-1.1 times the expression of different inflammatory factors in normal cells; after adding nano-micelle materials with different targets, the expression of different inflammatory factors was reduced to between 0.6-0.8 times the expression of normal cells. This part of the data shows that 3CsA-ASO nano-micelle materials with different targets have a good effect of downregulating inflammatory factor genes.
[0379] 9.3 Inhibitory effects of different target nanomicelles on inflammatory factors
[0380] HCEC cells were cultured at a rate of 5 × 10 4 The cells / well were seeded in a 12-well plate and adhered to the wall. Then, they were stimulated with 100 ng / mL LPS for 12 h. The supernatant was removed and 1 mL of 3CsA-ASO was added to each well. IL-17-h Nanomicelles, 3CsA-ASO IL-1β-h Nanomicelles, 3CsA-ASO IL-23-h Nanomicelles and 3CsA-ASO TNF-α-h The cells were incubated at 37°C for 6 h before transfection and then replaced with DMEM medium. The supernatant was collected for ELISA to detect the expression of different inflammatory factors in HCEC cells. The experimental results are shown in Table 1. Fig.40 shown.
[0381] As can be seen from the figure, after LPS stimulation, the expression of various inflammatory factors in HCEC cells increased significantly, with the increase range being about 1.5-2.5 times that of normal cells; after adding Lipo2000 to transfect ASO with different targets, the expression of inflammatory factors decreased; the expression of inflammatory factors in HCEC cells treated with various nano-micelle materials decreased the most and returned to the level of normal cells. This part of the data shows that 3CsA-ASO nano-micelle materials with different targets have a good effect of down-regulating inflammatory factors.
[0382] 9.4 Therapeutic effects of different target nanomicelles on dry eye
[0383] The ocular dry eye model was constructed using 0.2% benzalkonium chloride in 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.). 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mouse, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine), 3CsA-ASO IL-17-m Nanomicelles, 3CsA-ASO IL-1β-m Nanomicelles, 3CsA-ASO IL-23-m Nanomicelles and 3CsA-ASO TNF-α-m The nano-micelle material (CsA concentration in each sample group was 400 μM) was used for eye drops, 5 μL was dropped into each eye once a day, once in the morning and once in the evening. The treatment effect was evaluated by sodium fluorescein staining and phenol red cotton thread on the 0th and 14th day of treatment. The experimental results are shown in the figure. Fig.41 shown.
[0384] The results of sodium fluorescein staining showed that the eye score of mice in the untreated control group dropped from 11 points to about 10 points, and the phenol red cotton thread tear test results increased from 1.5mm to about 1.8mm, with no significant improvement; the eye score of mice treated with CsA eye drops dropped from 11 points to about 8 points, and the phenol red cotton thread tear test results increased from 1.5mm to about 3mm; the sodium fluorescein staining score of mice in the 3CsA-ASO nanomicelle material group with different targets dropped from about 11 points to about 5.5 points, and the phenol red cotton thread infiltration length increased from 1mm to about 3mm. From these partial data results, it can be seen that the drug-antisense oligonucleotide conjugate nanomicelles targeting different inflammatory factor targets have a significant therapeutic effect on the treatment of dry eyes in mice within two weeks.
[0385] Example 10. Self-assembled nanomicelles of cyclosporine A grafted with antisense oligonucleotides targeting different targets of NLRP3, JAK1 and PDE4 for the treatment of dry eye disease
[0386] 10.1 Synthesis and Characterization of Bromocyclosporine A (CsA-Br)
[0387] The synthesis of brominated cyclosporine A (CsA-Br) was carried out according to the corresponding synthesis steps in Example 6.
[0388] 10.2 Preparation and characterization of brominated cyclosporine A grafted with PS-ASO of different targets and nanomicelles
[0389] The antisense oligonucleotide sequences targeting different intracellular inflammatory pathway genes used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We chose to perform thiolation (PS) modification in the nucleic acid phosphate backbone so that it can undergo substitution reaction with the bromoacetyl bromide group modified on CsA-Br for efficient coupling. The sequence is as follows:
[0390] The antisense oligonucleotide sequences targeting different human inflammatory factor genes are:
[0391] NLRP3 human(20PS-ASO NLRP3-h )
[0392] 5'-AGCTGCTGCCCCGACCCAAACC TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(SEQ ID NO.59)
[0393] JAK1 human(20PS-ASO JAK1-h )
[0394] 5'-TTCGTCATCCTTGTAATCCAT TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(SEQ ID NO.60)
[0395] PDE4 human(20PSASO PDE4-h )
[0396] 5'-TTGATTTCCAGACCGAC TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(SEQ ID NO.61)
[0397] The antisense oligonucleotide sequences targeting different mouse inflammatory factor genes are:
[0398] NLRP3 mouse (20PS-ASO NLRP3-m )
[0399] 5′-GATTTAAGTACATTTCACC TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3′(SEQ ID NO.62)
[0400] JAK1 mouse (20PS-ASO JAK1-m )
[0401] 5'-TTGGAGAATGTCGCCATACAG TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(SEQ ID NO.63)
[0402] PDE4 mouse (20PS ASO PDE4-m )
[0403] 5'-TTGTCCTCTCTACACGCTCA TTTTT T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T*T-3'(SEQ ID NO.64)
[0404] The synthesis method is as follows: 400 times the molar equivalent of CsA-Br is dissolved in DMSO, 5OD of 20PS-ASO with different targets is added to make the reaction concentration 200μM, and then placed at 50°C for shaking reaction for 24h. After adding water, the excess CsA-Br in the reaction is removed by extraction with ethyl acetate, and 20CsA-ASO is obtained after concentration and evaporation. NLRP3 、20CsA-ASO JAK1 and 20CsA-ASO PDE4 The conjugate molecules were then redissolved in 50 μL DMSO solution and dropped into 500 μL PBS to assemble into 20CsA-ASO. NLRP3 Nanomicelles, 20CsA-ASO JAK1 Nanomicelles and 20CsA-ASO PDE4 The nanomicelles were then dialyzed in PBS to remove DMSO to obtain different nanomicelle materials dispersed in PBS solution.
[0405] 10.3 Regulatory effects of different target nanomicelles on target genes
[0406] HCEC cells were cultured at a rate of 1×10 5 The cells were seeded at a density of 1.54 × 10 / well in a 6-well plate and then stimulated with 100 ng / mL LPS for 12 h. After removing the supernatant, 1 mL of 20CsA-ASO was added to each well. NLRP3-h Nanomicelles, 20CsA-ASO JAK1-h Nanomicelles and 20CsA-ASO PDE4-hThe cells were incubated at 37°C for 6 h before transfection and then replaced with DMEM medium. After 48 h of incubation, RNA was extracted for PCR experiments to test the mRNA expression levels of different targets in HCEC cells. Fig.42 shown.
[0407] As can be seen from the figure, after LPS stimulation, the mRNA expression of different inflammatory factors was upregulated, about 1.3 to 1.5 times the normal cell expression. After adding Lipo2000 to transfect ASO with different targets, the expression of different inflammatory factors was reduced to 1-1.2 times the normal cell expression; after adding nano-micelle materials with different targets, the expression of different inflammatory factors was reduced to about 0.8 times the normal cell expression. This part of the data shows that the 20CsA-ASO nano-micelle materials with different targets have a good effect of downregulating inflammatory factor genes.
[0408] 10.4 Therapeutic effects of different target nanomicelles on dry eye
[0409] The ocular dry eye model was established in 6-8 week old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) using 0.2% benzalkonium chloride. 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mice once in the morning and evening every day. Two weeks after the model was established, cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Shanghai Fudan University School of Medicine), 20CsA-ASO NLRP3-m Nanomicelles, 20CsA-ASO JAK1-m Nanomicelles and 20CsA-ASO PDE4-m Nano-micelle material (CsA concentration in each sample group was 400 μM) was used for eye drops, 5 μL was dropped into each eye once a day, once in the morning and once in the evening. Fluorescein sodium staining and phenol red cotton thread were used to evaluate the therapeutic effect on the 0th and 14th days of treatment. The experimental results are shown in the figure. Fig.43 shown.
[0410] The results of fluorescein sodium staining showed that the eye score of mice in the untreated control group dropped from 13 points to about 12 points, and the phenol red cotton thread tear test results increased from 0.5mm to about 1mm, with no significant improvement; after CsA eye drops treatment, the eye score of mice dropped from 13 points to about 10 points, and the phenol red cotton thread tear test results increased from 1.5mm to about 2.5mm; the fluorescein sodium staining score of mice in the 20CsA-ASO nanomicelle material group with different targets dropped from about 13 points to about 7.5 points, and the phenol red cotton thread infiltration length increased from 1mm to about 3.5mm. From these partial data results, it can be seen that the drug-antisense oligonucleotide conjugate nanomicelles targeting different intracellular inflammatory targets have a significant therapeutic effect on the treatment of dry eyes in mice within two weeks.
[0411] Example 11: Use of rapamycin-antisense oligonucleotide conjugate and its nano-micelle assembly for the treatment of dry eye
[0412] 11.1 Synthesis of benzyl bromide-modified rapamycin (RAP-Bz-Br). The specific synthesis steps are shown in Fig.44
[0413] a) Synthesis of benzyl bromide modified thioketal (TK-Bz-Br). 3-Mercaptopropionic acid (2.2 equivalents), acetone (1 equivalent) and a catalytic amount of trifluoroacetic acid (TFA) were stirred at room temperature overnight, and then the resulting mixture was placed in an ice bath for cooling and crystallization. The prepared crystals were filtered and further washed with n-hexane, and then dried overnight at 45°C in a vacuum oven to obtain a white product, thereby preparing a thioketal compound (compound TK) with reactive oxygen species (ROS) response cracking characteristics. Further, 4-bromomethylbenzyl alcohol (1 equivalent) and compound TK (3 equivalents) were dissolved in ultra-dry dichloromethane, and then 4-dimethylaminopyridine (DMAP, 0.5 equivalents) was added. After stirring at room temperature for 5 minutes, dicyclohexylcarbodiimide (DCC, 1.2 equivalents, dissolved in ultra-dry dichloromethane) was added dropwise, and the reaction progress was detected by silica gel thin layer chromatography during the reaction. After the reaction, impurities were removed by filtration, the solvent in the filtrate was evaporated to dryness by rotary evaporator, and the benzyl bromide-modified ketalthioate (compound TK-Bz-Br) was purified by silica gel column chromatography. The eluent during the chromatography purification process was a petroleum ether / ethyl acetate mixed solution, and the final yield was 65%. The product was analyzed and detected by nuclear magnetic resonance spectroscopy. The nuclear magnetic resonance spectrum and the attribution of each peak are shown in Fig.45 .
[0414] b) Dissolve 1 g of rapamycin (RAP, 1 equivalent) in 20 mL of ethyl acetate. Stir the mixture in an ice bath, add imidazole (10 equivalents) and stir until dissolved. At the same time, dissolve trimethylsilyl chloride (TMS-Cl) in 5 mL of ethyl acetate and drip it dropwise into the above reaction solution, stir for about 2 hours, and obtain an intermediate product (compound RAP-31,42-bis-O-TMS) in which both positions 31 and 42 of rapamycin are protected by TMS. Then drip 6 mL of 0.5 M sulfuric acid (H2SO4) solution dropwise into the above mixture and place it in an ice bath overnight. After adding 60 mL of ethyl acetate to the reaction solution, extract it with saturated sodium bicarbonate (NaHCO3, 2 times) and deionized water (3 times), respectively, and control the pH of the aqueous solution layer between 6.0 and 7.0. Collect the ethyl acetate solution, then add anhydrous sodium sulfate to remove the water, and evaporate to dryness by rotary evaporation to obtain rapamycin (compound RAP-31-O-TMS) in which only the hydroxyl group at position 31 is protected by TMS. The yield of compound RAP-31-O-TMS is 90%. The mass spectrometry showed that its m / z is 1008.61, which can be attributed to [M+Na] + . The compound TK-Bz-Br (1 equivalent) obtained in a) and the compound RAP-31-O-TMS (0.8 equivalent) were dissolved in anhydrous dichloromethane, DMAP (0.5 equivalent) was added at room temperature, and stirred until dissolved. Then diisopropylcarbodiimide (DIC, 2 equivalents) dissolved in dichloromethane was added, and the mixture was stirred at room temperature overnight. The product was purified by silica gel column chromatography to obtain the compound RAP-31-O-TMS-42-Bz-Br. The yield of the compound RAP-31-O-TMS-42-Bz-Br was 35%; mass spectrometry showed that its m / z was 1419.64 / 1421.64, which can be attributed to [M+NH4] + The results of hydrogen and carbon nuclear magnetic resonance spectra are as follows Fig.46 . Finally, 0.4 g of compound RAP-31-O-TMS-42-Bz-Br was dissolved in a mixed solution of 10 mL acetonitrile and 20 mL ethyl acetate, 3 mL 1M H2SO4 was slowly added dropwise and stirred continuously for 2 h, and finally 50 mL ethyl acetate was added, and 50 mL was added for washing twice and extraction. After collecting the ethyl acetate layer, the water was removed with anhydrous sodium sulfate and then evaporated to dryness to obtain the final product benzyl bromide-modified rapamycin (compound RAP-Bz-Br), the yield of compound RAP-Bz-Br: 85%, and the mass spectrometry detection obtained m / z: 1347.59 / 1349.59, which can be attributed to [M+NH4] + .
[0415] 11.2 Synthesis of 10 Rapamycin Molecules-NFKBIZ Antisense Oligonucleotide Conjugates (10RAP-ASO NFKBIZ )
[0416] The nucleotide sequences targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We chose to perform thio (PS) modification in the nucleic acid phosphate backbone so that it can react with the bromoacetyl bromide group modified on CsA-Br for efficient coupling. The sequence is as follows:
[0417] Among them, antisense oligonucleotides (ASOs) targeting the human NFKBIZ gene NFKBIZ-h ) sequence is
[0418] Human:5'-ATCAGACAACGAATCGGGC TTT T*T*T*T*T*T*T*T*T*T*T-3'; (SEQ IDNO.65)
[0419] Among them, the antisense oligonucleotide (ASO) targeting the mouse NFKBIZ gene NFKBIZ-m ) sequence is
[0420] Mouse:5'-AATACTGGTACATTGACGCC TTT T*T*T*T*T*T*T*T*T*T*T-3' (SEQ ID NO. 66).
[0421] 10 rapamycin molecules-NFKBIZ antisense oligonucleotide conjugate (10RAP-ASO NFKBIZ ) The synthesis method is as follows: 2.2 mg of the compound RAP-Bz-Br (1.63 μmol) is dissolved in 100 μL DMSO, and then 5 OD ASO (20.55 nmol) is added, and the mixture is shaken at 50°C for 1 hour. Then water is added, and the excess RAP-Bz-Br in the reaction is removed by extraction with ethyl acetate, and after concentration and evaporation, 10 RAP-ASO is obtained. NFKBIZ The obtained product was verified by 15% denaturing polyacrylamide gel electrophoresis to be successfully grafted with rapamycin. Fig.47 .
[0422] 11.310 Rapamycin-NFKBIZ antisense oligonucleotide conjugate (10RAP-ASO NFKBIZ ) Preparation and characterization of nanomicelles
[0423] 10RAP-ASO NFKBIZ The conjugate (10OD ASO) was dissolved in 100μL DMSO and added dropwise to 300μL of continuously stirred phosphate buffered saline (PBS). The solution was then placed in a dialysis bag and dialyzed against PBS overnight to remove DMSO. After centrifugation at 3000rpm for 5min, 10RAP-ASO was obtained. NFKBIZNanomicelles. The hydrated particle size and morphology were characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Fig.48 shown.
[0424] 11.410RAP-ASO NFKBIZ-h Gene regulation by nanomicelles
[0425] Human corneal epithelial cells (HCEC) were cultured at a rate of 1×10 5 The cells were seeded at a density of 100 ng / mL in a 6-well plate and cultured overnight. 100 ng / mL LPS was added for stimulation overnight. 1 mL of ASO was added to each well. NFKBIZ-h +Lipo2000 complex and 10RAP-ASO NFKBIZ-h The cells were incubated with Opti-MEM medium (ASO concentration was 10 μM) at 37°C for 6 h, then replaced with DMEM medium and incubated at 37°C for 48 h. The cells were then collected and RNA was extracted for real-time fluorescence quantitative PCR (RT-qPCR) to evaluate the expression level of NFKBIZ mRNA in HCEC cells. The experimental results are shown in Fig.49 As shown in the figure, the expression level of NFKBIZ mRNA in HCEC cells after LPS stimulation is about 1.4 times that of normal cells. NFKBIZ-h The expression level of NFKBIZ mRNA was about 0.75 times of normal cells. NFKBIZ-h After co-incubation with nano-micelles, the expression of NFKBIZ mRNA dropped to about 0.6 times of normal cells. NFKBIZ-h Nanomicelles can effectively regulate NFKIBZ gene expression in HCEC cells and significantly knock down NFKBIZ mRNA expression.
[0426] 11.510RAP-ASO NFKBIZ-m Nano-micelles for the treatment of dry eye
[0427] The dry eye model was constructed using 0.2% benzalkonium chloride. Mice aged 6 to 8 weeks (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) were selected. 5 μL of 0.2% benzalkonium chloride was dripped into each eye of the mice, once in the morning and evening every day, for two consecutive weeks. After the model was successfully established, different drugs were used for eye drops treatment, and the groups were divided into the following groups: untreated group (mock), hospital-prepared cyclosporine A eye drops (400 μM CsA, provided by the Eye, Ear, Nose and Throat Specialty Hospital Affiliated to Fudan University School of Medicine), and 10RAP-ASO NFKBIZ-mNano-micelles (400 μM rapamycin). 5 μL was dripped into each eye once in the morning and evening. Fluorescein sodium staining and phenol red cotton thread were used to evaluate the therapeutic effect on the 0th, 7th, and 14th days of treatment. The experimental results are as follows Fig.50 As shown. For the untreated control group (control group), after 14 days of treatment, the sodium fluorescein staining score and the phenol red cotton thread test results were not much different from those before treatment, indicating that the eyes of untreated dry eye mice will not return to normal on their own. For the CsA eye drops group, the sodium fluorescein staining score decreased slightly after treatment, and the tear secretion measured by the phenol red cotton thread increased, and the effect was more obvious with the increase in treatment time. However, after 14 days of treatment, the tear secretion measured by the phenol red cotton thread averaged ~3mm, which did not return to normal. For 10RAP-ASO NFKBIZ-m The treatment effect was the most significant in the nano-micelle experimental group. After 14 days of treatment, the sodium fluorescein staining score was the lowest, with an average of 5, and the tear secretion was the highest, with an average of 4 mm.
[0428] Example 12 Cyclosporine A trimer (CsA3) and NFKBIZ antisense oligonucleotide covalent conjugate (CsA3-ASO NFKBIZ ) and its nano-micelle assembly structure for the treatment of psoriasis
[0429] 12.1CsA3-ASO NFKBIZ Synthesis of covalent conjugates
[0430] CsA3-ASO used NFKBIZ The covalent conjugate is the same as the conjugate used in Example 5, and its specific synthesis steps are shown in Sections 5.1-5.2 of the Example.
[0431] 12.2CsA3-ASO NFKBIZ Preparation and characterization of self-assembled nanomicelles
[0432] Cyclosporine A nanomicelles (CsA3-ASO NFKBIZ For the preparation and characterization steps of nanomicelles, please refer to Section 5.3 of the Examples.
[0433] 12.3CsA3-ASO NFKBIZ-h Regulatory effects of nanomicelles on target genes
[0434] 1×10 5 Human keratinocyte cell line HaCaT cells were placed in a 6-well plate and then stimulated with 100 ng / mL recombinant human interleukin-36 (IL-36) for 2 h. After washing with 1× PBS buffer solution, 1 mL of ASO was added to each well. NFKBIZ-h +Lipo2000 complex, CsA3-ASO NFKBIZ-hNanomicelle Opti-MEM culture medium (ASO per group of samples NFKBIZ-h The concentration of 10 μM was added to the well plate and incubated with HaCaT cells for 6 hours. Fresh DMEM medium was replaced. At the same time, cells without any treatment or only stimulated with IL-36 were used as controls. After incubation at 37°C for 48 hours, RNA was extracted for RT-qPCR experiments to examine the expression level of NFKBIZ mRNA in HaCaT cells. The experimental results are shown in Fig.51 shown.
[0435] As can be seen from the figure, the expression of NFKBIZ mRNA in HaCaT cells stimulated by IL-36 increased to about 2.1 times that of normal cells. NFKBIZ-h It can be lowered to around 1.2, CsA3-ASO NFKBIZ-h Nano-micelles down-regulated the NFKBIZ gene to about 0.8, so compared with a single ASO NFKBIZ-h , CsA3-ASO NFKBIZ-h Nanomicelles have a better ability to downregulate the expression of NFKBIZ gene.
[0436] 12.4CsA3-ASO NFKBIZ Regulatory effect of nanomicelles on inflammatory factors
[0437] 5×10 4 HaCaT cells, a human keratinocyte cell line, were placed in a 12-well plate and adhered to the wall. They were then stimulated with 100 ng / mL recombinant human interleukin-36 (IL-36) for 2 h. After washing with 1× PBS buffer solution, 1 mL of ASO was added to each well. NFKBIZ-h +Lipo2000 complex, CsA3-ASO NFKBIZ-h Nanomicelle Opti-MEM culture medium (ASO per group of samples NFKBIZ-h The concentration of 10 μM) was added to the well plate and incubated with HaCaT cells for 6 hours. Fresh DMEM medium was replaced. At the same time, cells without any treatment or only stimulated with IL-36 were used as controls. After incubation at 37°C for 48 hours, the supernatant was collected and the secretion levels of TNFα, IL-17A and IL-33 were detected by ELISA kits. The experimental results are shown in Fig.52 shown.
[0438] As can be seen from the figure, the levels of TNFα, IL-17A and IL-33 in HaCaT cells stimulated by IL-36 increased to about 2.1 times, 1.7 times and 2.0 times of those in unstimulated cells, respectively. NFKBIZ-hThe levels of TNFα, IL-17A and IL-33 can be downregulated to about 1.1, 1.0 and 0.9 times, respectively. NFKBIZ-h Nano-micelles down-regulated the levels of TNFα, IL-17A, and IL-33 by about 0.8-0.9 times, thus compared with single ASO NFKBIZ-h , CsA3-ASO NFKBIZ-h Nanomicelles have stronger inhibitory effects on inflammatory factors such as TNFα, IL-17A and IL-33.
[0439] 12.5CsA3-ASO NFKBIZ-m The therapeutic effect of nano-micelles on psoriasis
[0440] The psoriasis model of the back and ears of 6-8 week-old mice (C57BL / 6, Suzhou Xishan Biotechnology Co., Ltd.) was established using 5% imiquimod cream. After removing the hair on the back of the mice, 60 mg of 5% imiquimod cream was applied to the back and ears of each mouse for 6 consecutive days. Fig.53 The mice showed obvious psoriasis-like phenotypes such as erythema, scaling, and obvious thickening of the skin on their backs and ears, indicating that the model was successfully established. NFKBIZ-m After the nano-micelles were mixed with carbomer gel, they were applied to the lesions for treatment. NFKBIZ-m Nano-micelle carbomer gel was used as a control group for efficacy testing. On the 7th day of treatment, the thickness of the skin at the back lesions and the thickness of the ears were measured, and the erythema, scaling, skin thickening and severity of the psoriasis lesion area were scored. Fig.54 , Fig.55 and Fig.56 After 7 days of treatment, CsA3-ASO NFKBIZ-m The erythema and scaling of the skin lesions of mice in the nano-micelle group were significantly reduced, and the skin thickness of the ears and lesions was reduced. These results showed that CsA3-ASO NFKBIZ-m Nanomicelles effectively alleviated the psoriasis-like phenotype in diseased mice.
[0441] Example 13 Covalent conjugate of triamcinolone acetonide molecule and NFKBIZ antisense oligonucleotide (10TA-ASO NFKBIZ ) and its nano-micelle assembly structure for synergistic treatment of psoriasis
[0442] 13.1 Synthesis of triamcinolone acetonide bromide (TA-Br)
[0443] The specific synthesis steps of triamcinolone acetonide bromide (TA-Br) are shown in Fig.57First, under nitrogen protection, triamcinolone acetonide (200 mg) was placed in a dry 250 mL round-bottom flask, 50 mL of anhydrous dichloromethane was added to dissolve, 130 μL of N, N-diisopropylethylamine was added dropwise, 105 mg of bromoacetyl bromide was added dropwise under ice bath conditions, the mixture was transferred to room temperature, and the mixture was stirred for 12 h. After the reaction was completed, 50 mL of saturated sodium bicarbonate solution was added to wash 3 times, and 50 mL of saturated sodium chloride solution was added to wash once. The organic phase was collected, dried over anhydrous sodium sulfate, and the organic phase was concentrated by distillation under reduced pressure. The organic phase was separated by silica gel column chromatography, and the eluent was petroleum ether / ethyl acetate to obtain a light yellow solid (140 mg), that is, carbonylethyl triamcinolone acetonide bromide was obtained.
[0444] Triamcinolone acetonide bromide 1 HNMR spectra, such as Fig.58 As shown, the test solvent DMSO-d6, the attribution of each proton peak is as follows: δ (ppm): 7.30 (1H, d), 6.25 (1H, dd), 6.02 (1H, s), 5.50 (1H, s), 5.27 (1H, d), 4.86 (1H, d), 4.82 (1H, d), 4.32-4.15 (2H, d), 4.21 (1H, s), 3.7 8(6H,s),2.64(1H,m),2.34(1H,dd),2.05(1H,m),1.95(1H,q),1.82(1H,t),1.73(1H,d),1.55(2H,m),1.50(3H,s),1.35(4H,s),1.26(1H,t),1.16(3H,s),0.80(3H,s). 13 C NMR spectrum, such as Fig.59 As shown, the test solvent is DMSO-d6, and the characteristic carbons after coupling with carbonylethyl bromide are as follows: 210.50, 185.68, 167.04, 153.19, 129.78, 124.69, 110.83, 102.06, 97.28, 81.62, 70.66, 66.28, 48.43, 45.14, 42.95, 35.48, 33.47, 32.89, 30.57, 27.95, 26.77, 25.72, 23.26, and 16.83. The theoretical molecular weight of carboethyl triamcinolone acetonide bromide is 555.43, and the molecular weights measured by HPLC / quadrupole flight mass spectrometry are 557.1391 and 1113.2782, corresponding to [M+1] + and [2M+1] + peak, confirming that the target product was successfully synthesized. Fig.60 shown.
[0445] 13.2 Synthesis of triamcinolone acetonide-NFKBIZ antisense oligonucleotide conjugate (10TA-ASO NFKBIZ )
[0446] The nucleotide sequences targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We chose to perform thio (PS) modification in the nucleic acid phosphate backbone so that it could react with the carbonylethyl bromide group modified on TA-Br for efficient coupling. The sequence is as follows:
[0447] Among them, antisense oligonucleotides (ASOs) targeting the human NFKBIZ gene NFKBIZ-h ) sequence is
[0448] Human:5'-ATCAGACAACGAATCGGGC TTT T*T*T*T*T*T*T*T*T*T*T-3'; (SEQ IDNO.67)
[0449] Among them, the antisense oligonucleotide (ASO) targeting the mouse NFKBIZ gene NFKBIZ-m ) sequence is
[0450] Mouse:5'-AATACTGGTACATTGACGCC TTT T*T*T*T*T*T*T*T*T*T*T-3' (SEQ ID NO. 68).
[0451] 10TA-ASO NFKBIZ The synthesis method of the covalent conjugate is as follows: dissolve the carbonylethyl triamcinolone acetonide bromide compound in 20 μL of dimethyl sulfoxide solution, add 2 μL of thiophosphate group-modified antisense oligonucleotide solution, the oligonucleotide concentration is 200 μM (the ratio of thiophosphate group to carbonylethyl triamcinolone acetonide bromide is 1:1 to 1:50), place at 55°C, and shake to react overnight. After the reaction is completed, add 500 μL of ultrapure water, use ethyl acetate to extract multiple times to remove the excess carbonylethyl triamcinolone acetonide bromide in the reaction, distill under reduced pressure to remove the solvent, and then redissolve in ultrapure water to obtain triamcinolone acetonide-antisense oligonucleotide conjugate. The successful grafting of carbonylethyl triamcinolone acetonide bromide to the thiophosphate-modified oligonucleotide was verified by 15% denaturing polyacrylamide gel electrophoresis, see Fig.61 .
[0452] 13.310TA-ASO NFKBIZ Preparation and characterization of nanomicelles
[0453] 10TA-ASO NFKBIZThe covalent conjugate (10ODASO) was dissolved in 100μL DMSO and added dropwise to 300μL of 1×PBS buffer solution that was continuously stirred. The solution was then placed in a dialysis bag and dialyzed against PBS overnight to remove DMSO to obtain 10TA-ASO. NFKBIZ Nanomicelle particles. Characterization of 10TA-ASO by 1% agarose gel electrophoresis NFKBIZ The successful preparation of nanomicelles, such as Fig.62 shown.
[0454] 13.410TA-ASO NFKBIZ Gene regulation by nanomicelles
[0455] 1×10 5 Human keratinocyte cell line HaCaT cells were placed in a 6-well plate and then stimulated with 100 ng / mL recombinant human interleukin-36 (IL-36) for 2 h. After washing with 1× PBS buffer solution, 1 mL of ASO was added to each well. NFKBIZ-h +Lipo2000 complex, 10TA-ASO NFKBIZ-h Nanomicelle Opti-MEM culture medium (ASO per group of samples NFKBIZ-h The concentration of 10 μM was added to the well plate and incubated with HaCaT cells for 6 hours. Fresh DMEM medium was replaced. At the same time, cells without any treatment or only stimulated with IL-36 were used as controls. After incubation at 37°C for 48 hours, RNA was extracted for RT-qPCR experiments to examine the expression level of NFKBIZ mRNA in HaCaT cells. The experimental results are shown in Fig.63 shown.
[0456] from Fig.63 It can be seen that the expression of NFKBIZ mRNA in HaCAT cells stimulated by IL-36 increased to about 2.2 times that of normal cells, and the ASO after Lipo2000 transfection NFKBIZ-h It can be adjusted down to about 0.85, 10TA-ASO NFKBIZ-h Nano-micelles down-regulated the NFKBIZ gene to about 0.7, so compared with a single ASO NFKBIZ-h , 10TA-ASO NFKBIZ-h Nanomicelles have a better ability to downregulate the expression of NFKBIZ gene.
[0457] 13.510TA-ASO NFKBIZ-m The therapeutic effect of nano-micelles on psoriasis
[0458] A psoriasis model of the back and ears of 6-8 week-old mice was constructed using 5% imiquimod cream. After removing the hair on the back of the mice, 60 mg of 5% imiquimod cream was applied to the back and ears of each mouse for 6 consecutive days. After 6 days of modeling, the mice showed obvious psoriasis-like phenotypes such as erythema, scaling, and obvious thickening of the skin on the back and ears, indicating that the model was successfully constructed. NFKBIZ-m After the nano-micelles were mixed with carbomer gel, they were applied to the lesions for treatment. NFKBIZ-m Nano-micelle carbomer gel was used as a control group for efficacy testing. On the 7th day of treatment, the thickness of the skin at the back lesions and the thickness of the ears were measured, and the erythema, scaling, skin thickening and severity of the psoriasis lesion area were scored. Fig.64 , Fig.65 and Fig.66 As shown in the figure, after 7 days of treatment, 10TA-ASO NFKBIZ-m The erythema and scaling of the skin lesions of mice in the nano-micelle group were significantly reduced, and the skin thickness of the lesions was reduced, indicating that 10TA-ASO NFKBIZ-m Nanomicelles effectively alleviated the psoriasis-like phenotype in diseased mice.
[0459] Example 14 Covalent conjugate of calcipotriol molecule and NFKBIZ antisense oligonucleotide (10Cal-ASO NFKBIZ ) and its nano-micelle assembly structure for synergistic treatment of psoriasis
[0460] 14.1 Synthesis of Benzyl Bromide-Modified Calcipotriol (Cal-Bz-Br)
[0461] The synthesis steps of benzyl bromide-modified calcipotriol (Cal-Bz-Br) are shown in Fig.67 , including a) the synthesis of benzyl bromide-modified dithiodipropionic acid (DTPA-Bz-Br). Take 500 mg of 4-bromomethylbenzyl alcohol and 2.6 g of 3,3'-dithiodipropionic acid (DTPA) and dissolve them in a mixed solution of ultra-dry dichloromethane and tetrahydrofuran (1 / 1, v / v); then add 91 mg of 4-dimethylaminopyridine, stir for 5 minutes, and then dropwise add 615 mg of dicyclohexylcarbodiimide (dissolved in ultra-dry dichloromethane). After reacting at room temperature overnight, use a rotary evaporator to evaporate the solvent, and separate by silica gel column chromatography to obtain a benzyl bromide structure (DTPA-Bz-Br) containing a disulfide bond, and the eluent is petroleum ether / ethyl acetate. Product 1 H NMR and assignments are shown in Fig.68 .
[0462] b) Take 135 mg of calcipotriol (Cal) and 81 mg of dicyclohexylcarbodiimide, add 30 mL of anhydrous dichloromethane and stir to dissolve, add 10 mg of 4-dimethylaminopyridine (dissolved in anhydrous dichloromethane), add 10 mg of DTPA-Bz-Br (dissolved in anhydrous dichloromethane), stir at room temperature for 3 hours, evaporate the solvent by rotary evaporator, and separate by silica gel column chromatography to obtain benzyl bromide modified calcipotriol prodrug molecule (Cal-Bz-Br), the eluent is petroleum ether / ethyl acetate system. The NMR image of the product is shown in Fig.69 , the test solvent is DMSO-d6, and the attribution of each proton peak is as follows: δ (ppm): 7.43, H3 (2H, s), 7.36, H2 (2H, m), 6.35, H10 (1H, d), 6.02H9 (1H, d), 5.52, H12 (2H, m), 5.35, H17 (1H, d), 5.14, H4 (2H, s), 5.06, H8 (1H, d), 4.51, H1 (2H, s), 4.15, H14 (1H, m), 3.48, H13 (1H, m), 2.94, H15 (2H, m), 2.91, H16 (2H, m), 0.58, H11 (3H, d), 0.52, H6 (2H, m), 0.33, H5 (1H, m), 0.25, H7 (1H, m). The theoretical molecular weight of Cal-Bz-Br is 785.2, and the molecular weight measured by HPLC / quadrupole flight mass spectrometry is 786.25, corresponding to [M+1] of Cal-Bz-Br. + peak, confirming that the target product was successfully synthesized. Fig.70 shown.
[0463] 14.2 Synthesis of Calcipotriol-NFKBIZ Antisense Oligonucleotide Conjugate (10Cal-ASO NFKBIZ )
[0464] The nucleotide sequences targeting the NFKBIZ gene used in this example were purchased from Sangon Biotech (Shanghai) Co., Ltd. We chose to perform thio (PS) modification in the nucleic acid phosphate backbone so that it can react with the bromo group modified on Cal-Br for efficient coupling. The sequence is as follows:
[0465] Among them, antisense oligonucleotides (ASOs) targeting the human NFKBIZ gene NFKBIZ-h ) sequence is
[0466] Human:5'-ATCAGACAACGAATCGGGC TTT T*T*T*T*T*T*T*T*T*T*T-3'(SEQ IDNO.69);
[0467] Among them, the antisense oligonucleotide (ASO) targeting the mouse NFKBIZ gene NFKBIZ-m ) sequence is
[0468] Mouse:5'-AATACTGGTACATTGACGCC TTT T*T*T*T*T*T*T*T*T*T*T-3' (SEQ ID NO. 70).
[0469] Calcipotriol-NFKBIZ antisense oligonucleotide conjugate (10Cal-ASO NFKBIZ ) The synthesis method is: take the Cal-Bz-Br compound and dissolve it in 20 μL of dimethyl sulfoxide solution, add 2 μL of thiophosphate group modified antisense oligonucleotide solution, the oligonucleotide concentration is 200 μM (the ratio of thiophosphate group to Cal-Bz-Br compound is 1:5), place it at 55°C, and shake it overnight. After the reaction is completed, add 500 μL of ultrapure water, use ethyl acetate to extract multiple times to remove the excess Cal-Bz-Br compound in the reaction, and after the solvent is removed by vacuum distillation, the calcipotriol-antisense oligonucleotide conjugate prodrug is obtained. The successful grafting of calcipotriol to the thiophosphate modified oligonucleotide was verified by 15% denaturing polyacrylamide (PAGE) gel electrophoresis, see Fig.71 .
[0470] 14.310Cal-ASO NFKBIZ Preparation and characterization of nanomicelles
[0471] 10Cal-ASO NFKBIZ The conjugate (10OD ASO) was dissolved in 100μL DMSO and added dropwise to 300μL of 1×PBS buffer solution that was continuously stirred. The solution was then placed in a dialysis bag and dialyzed against PBS overnight to remove DMSO to obtain 10Cal-ASO. NFKBIZ Nanomicelle particles. The successful assembly was confirmed by 1% agarose gel electrophoresis. Fig.72 In addition, the hydrated particle size of the calcipotriol-antisense oligonucleotide conjugate self-assembled nanomicelles was determined by dynamic light scattering. Fig.73 As shown, the hydrated particle size of the calcipotriol-antisense oligonucleotide conjugate self-assembled nanomicelles is about 150 nm. Fig.73 The transmission electron microscopy image shows that the prepared nanomicelles are spherical in shape. NFKBIZ The critical micelle concentration of the conjugate was determined to be 0.527 μM. Fig.74 .
[0472] 14.410Cal-ASO NFKBIZ Gene regulation by nanomicelles
[0473] 1×10 5 Human keratinocyte cell line HaCaT cells were placed in a 6-well plate and then stimulated with 100 ng / mL recombinant human interleukin-36 (IL-36) for 2 h. After washing with 1× PBS buffer solution, 1 mL of ASO was added to each well. NFKBIZ-h +Lipo2000 complex, 10Cal-ASO NFKBIZ-h Nanomicelle Opti-MEM culture medium (ASO per group of samples NFKBIZ-h The concentration of 10 μM was added to the well plate and incubated with HaCaT cells for 6 hours. Fresh DMEM medium was replaced. At the same time, cells without any treatment or only stimulated with IL-36 were used as controls. After incubation at 37°C for 48 hours, RNA was extracted for RT-qPCR experiments to examine the expression level of NFKBIZ mRNA in HaCaT cells. The experimental results are shown in Fig.75 shown.
[0474] As can be seen from the figure, the expression of NFKBIZ mRNA in HaCaT cells stimulated by IL-36 increased to about 1.9 times that of normal cells. NFKBIZ-h It can be adjusted down to about 0.85 times, 10Cal-ASO NFKBIZ-h Nano-micelles down-regulated the NFKBIZ gene by about 0.65 times, so compared with a single ASO NFKBIZ-h , 10Cal-ASO NFKBIZ-h Nanomicelles have a better ability to downregulate the expression of NFKBIZ gene.
[0475] 14.510Cal-ASO NFKBIZ-m The therapeutic effect of nano-micelles on psoriasis
[0476] A 5% imiquimod cream (Sichuan Mingxin Pharmaceutical Co., Ltd.) was used to construct a psoriasis model on the back and ears of 6-8 week-old mice. After removing the hair on the back of the mice, 60 mg of 5% imiquimod cream was applied to the back and ears of each mouse for 6 consecutive days. After 6 days of modeling, the mice showed obvious psoriasis-like phenotypes such as erythema, scaling, and obvious thickening of the skin on the back and ears, indicating that the model was successfully constructed. 10Cal-ASO NFKBIZ-m After mixing the nano-micelles with carbomer gel, apply it to the lesions for treatment. NFKBIZ-m Nano-micelle carbomer gel was used as a control group for efficacy testing. On the 7th day of treatment, the thickness of the skin at the back lesions and the thickness of the ears were measured, and the erythema, scaling, skin thickening and severity of the psoriasis lesion area were scored. Fig.76 , Fig.77 as well as Fig.78 As shown in the figure, after 7 days of treatment, 10Cal-ASO NFKBIZ-m The erythema and scaling of the skin lesions of mice in the nano-micelle group were significantly reduced, and the skin thickness of the lesions was reduced, indicating that 10Cal-ASO NFKBIZ-m Nanomicelles effectively alleviated the psoriasis-like phenotype in diseased mice.
[0477] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention rather than all the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention. Sequence Listing <110> Zhejiang Yimou Biotechnology Co., Ltd. <120> A small molecule drug-oligonucleotide conjugate and its application <160> 70 <170> SIPOSequenceListing 1.0 <210> 1 <211> 19 <212> DNA <213> Artificial Sequence <400> 1 atcagacaac gaatcgggc 19 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <400> 2 aatactggta cattgacgcc 20 <210> 3 <211> twenty two <212> DNA <213> Artificial Sequence <400> 3 atcagacaac gaatcgggct tt 22 <210> 4 <211> twenty three <212> DNA <213> Artificial Sequence <400> 4 aatactggta cattgacgcc ttt 23 <210> 5 <211> twenty four <212> DNA <213> Artificial Sequence <400> 5 atcagacaac gaatcgggct tttt 24 <210> 6 <211> 25 <212> DNA <213> Artificial Sequence <400> 6 aatactggta cattgacgcc ttttt 25 <210> 7 <211> 19 <212> DNA <213> Artificial Sequence <400> 7 atcagacaac gaatcgggc 19 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <400> 8 aatactggta cattgacgcc 20 <210> 9 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 9 gcccgauucg uugucugaut t 21 <210> 10 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 10 aucagacaac gaaucgggct t 21 <210> 11 <211> twenty four <212> DNA / RNA <213> Artificial Sequence <400> 11 gcccgauucg uugucugaut tttt 24 <210> 12 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 12 aucagacaac gaaucgggct t 21 <210> 13 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 13 gcccgauucg uugucugattttttt 26 <210> 14 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 14 aucagacaac gaaucgggct t 21 <210> 15 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 15 gcgucaaugu accaguauut t 21 <210> 16 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 16 aauacuggua cauugacgcc t 21 <210> 17 <211> twenty four <212> DNA / RNA <213> Artificial Sequence <400> 17 gcgucaaugu accaguauut tttt 24 <210> 18 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 18 aauacuggua cauugacgcc t 21 <210> 19 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 19 gcgucaaugu accaguauuttttttt 26 <210> 20 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 20 aauacuggua cauugacgcc t 21 <210> twenty one <211> 45 <212> DNA <213> Artificial Sequence <400> twenty one atcagacaac gaatcgggct tttttttttt tttttttttt ttttt 45 <210> twenty two <211> 46 <212> DNA <213> Artificial Sequence <400> twenty two aatactggta cattgacgcc tttttttttt tttttttttt tttttt 46 <210> twenty three <211> 27 <212> DNA / RNA <213> Artificial Sequence <400> twenty three cucuaaugag uuuaguccga ttttttt 27 <210> twenty four <211> twenty two <212> DNA / RNA <213> Artificial Sequence <400> twenty four ucggacuaaa cucauuagag tt 22 <210> 25 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 25 aggcugaucu guugccguattttttt 26 <210> 26 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 26 uacggcaaca gaucagccut g 21 <210> 27 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 27 cagcaacccu gagucccuat tttttt 26 <210> 28 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 28 uagggacuca ggguugcugt t 21 <210> 29 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 29 gacaaccaac uaguggugcttttttt 26 <210> 30 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 30 gcaccacuag uugguuguct t 21 <210> 31 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 31 aagagauccu gguccugaattttttt 26 <210> 32 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 32 uucaggacca ggaucucuug c 21 <210> 33 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 33 ggaaggcagugucacucauttttttt 26 <210> 34 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 34 augagugaca cugccuucct t 21 <210> 35 <211> 32 <212> DNA / RNA <213> Artificial Sequence <400> 35 acaaccaucaccacacuggauacggttttttt 32 <210> 36 <211> 27 <212> DNA / RNA <213> Artificial Sequence <400> 36 ccguauccag uguggugaug guugutt 27 <210> 37 <211> 29 <212> DNA / RNA <213> Artificial Sequence <400> 37 gucucagccucuucucauccuttttttt 29 <210> 38 <211> twenty four <212> DNA / RNA <213> Artificial Sequence <400> 38 aggaaugaga agaggcugag actt 24 <210> 39 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 39 guggacuuga agaaauuuattttttt 26 <210> 40 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 40 uaaauuucuu caaguccact t 21 <210> 41 <211> 28 <212> DNA / RNA <213> Artificial Sequence <400> 41 ggauuacaag gaugacgaag gttttttt 28 <210> 42 <211> twenty three <212> DNA / RNA <213> Artificial Sequence <400> 42 uucgucaucc uuguaaucca utt 23 <210> 43 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 43 gagucggucu ggaaaucaat tttttt 26 <210> 44 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 44 uugauuucca gaccgacuct t 21 <210> 45 <211> 26 <212> DNA / RNA <213> Artificial Sequence <400> 45 ggugaaaugu acuuaaauct tttttt 26 <210> 46 <211> twenty one <212> DNA / RNA <213> Artificial Sequence <400> 46 gauuuaagua cauuucacct t 21 <210> 47 <211> 28 <212> DNA / RNA <213> Artificial Sequence <400> 47 cuguauggcg acauucucca attttttt 28 <210> 48 <211> twenty three <212> DNA / RNA <213> Artificial Sequence <400> 48 uuggagaaug ucgccauaca gtt 23 <210> 49 <211> 28 <212> DNA / RNA <213> Artificial Sequence <400> 49 augagcgugu agagaggaca attttttt 28 <210> 50 <211> twenty three <212> DNA / RNA <213> Artificial Sequence <400> 50 uuguccucuc uacacgcuca utt 23 <210> 51 <211> 27 <212> DNA <213> Artificial Sequence <400> 51 tcggactaaa ctcattagag ttttttt 27 <210> 52 <211> 27 <212> DNA <213> Artificial Sequence <400> 52 ggtacttctg ccatggctgc ttttttt 27 <210> 53 <211> 32 <212> DNA <213> Artificial Sequence <400> 53 cattacagct ctgctcccca gcatcttttt tt 32 <210> 54 <211> twenty three <212> DNA <213> Artificial Sequence <400> 54 cagtgctcat ggtgtctttt ttt 23 <210> 55 <211> 28 <212> DNA <213> Artificial Sequence <400> 55 ttcaggacca ggatctcttg cttttttt 28 <210> 56 <211> 26 <212> DNA <213> Artificial Sequence <400> 56 atgagtgaca ctgccttccttttttt 26 <210> 57 <211> 32 <212> DNA <213> Artificial Sequence <400> 57 ccgtatccag tgtggtgatg gttgtttttt tt 32 <210> 58 <211> 27 <212> DNA <213> Artificial Sequence <400> 58 aacccatcgg ctggcaccac ttttttt 27 <210> 59 <211> 48 <212> DNA <213> Artificial Sequence <400> 59 agctgctgcc ccgacccaaa cctttttttt tttttttttt tttttttt 48 <210> 60 <211> 47 <212> DNA <213> Artificial Sequence <400> 60 ttcgtcatcc ttgtaatcca tttttttttt tttttttttt ttttttt 47 <210> 61 <211> 43 <212> DNA <213> Artificial Sequence <400> 61 ttgatttcca gaccgacttt tttttttttt tttttttttt ttt 43 <210> 62 <211> 45 <212> DNA <213> Artificial Sequence <400> 62 gatttaagta catttcacctttttttttttttttttttttttttt 45 <210> 63 <211> 47 <212> DNA <213> Artificial Sequence <400> 63 ttggagaatg tcgccataca gttttttttt tttttttttt ttttttt 47 <210> 64 <211> 46 <212> DNA <213> Artificial Sequence <400> 64 ttgtcctctc tacacgctca tttttttttt tttttttttt tttttt 46 <210> 65 <211> 33 <212> DNA <213> Artificial Sequence <400> 65 atcagacaac gaatcgggct tttttttttt ttt 33 <210> 66 <211> 34 <212> DNA <213> Artificial Sequence <400> 66 aatactggta cattgacgcc tttttttttt tttt 34 <210> 67 <211> 33 <212> DNA <213> Artificial Sequence <400> 67 atcagacaac gaatcgggct tttttttttt ttt 33 <210> 68 <211> 34 <212> DNA <213> Artificial Sequence <400> 68 aatactggta cattgacgcc tttttttttt tttt 34 <210> 69 <211> 33 <212> DNA <213> Artificial Sequence <400> 69 atcagacaac gaatcgggct tttttttttt ttt 33 <210> 70 <211> 34 <212> DNA <213> Artificial Sequence <400> 70 aatactggta cattgacgcc tttttttttt tttt 34
Claims
1. A small molecule drug-oligonucleotide conjugate, which is obtained by covalently coupling a small molecule drug with immunomodulatory function and a functional oligonucleotide molecule capable of regulating the expression of inflammation-related genes; The small molecule drug is one or more of the calcineurin inhibitor cyclosporine A, the glucocorticoid triamcinolone acetonide, the mTOR inhibitor rapamycin, and the vitamin D analog calcipotriol; The inflammation-related gene is one or more of the tumor necrosis factor-α gene, interleukin 1b gene, interleukin 17 gene, interleukin 23 gene, NFKBIZ gene, inflammasome NLRP3 gene, JAK1 gene and PDE4 gene; The small molecule drug-oligonucleotide conjugate is nCsA-ASO NFKBIZ , nCsA-siRNA NFKBIZ , 3CsA-siRNA IL-17 , 3CsA-siRNA IL-1β , 3CsA-siRNA IL-23 , 3CsA-siRNA TNF-α , 3CsA-siRNA NLRP3 , 3CsA-siRNA JAK1 , 3CsA-siRNA PDE4 、3CsA-ASO IL-17 、3CsA-ASO IL-1β 、3CsA-ASO IL-23 、3CsA-ASO TNF-α 、20CsA-ASO NLRP3 、20CsA-ASO JAK1 、20CsA-ASO PDE4 、10RAP-ASO NFKBIZ 、CsA3-ASO NFKBIZ 、10TA-ASO NFKBIZ and 10Cal-ASO NFKBIZ One or more of the following; The nCsA-ASO NFKBIZ wherein n is any integer from 1 to 20; the nCsA-siRNA NFKBIZ Where n is 1, 2 or 3; When the nCsA-ASO NFKBIZ When n is 1, the nCsA-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.1, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.2; When the nCsA-ASO NFKBIZ When n is 2, the nCsA-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.3, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.4; When the nCsA-ASO NFKBIZ When n is 3, the nCsA-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.5, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.6; When the nCsA-ASO NFKBIZ When n is 20, the nCsA-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.21, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.22; When the nCsA-siRNA NFKBIZ When n is 1, the nCsA-siRNA NFKBIZ The sense chain sequence and antisense chain sequence of the siRNA targeting human NFKBIZ are shown in SEQ ID NO.9 and SEQ ID NO.10, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse NFKBIZ are shown in SEQ ID NO.15 and SEQ ID NO.16; When the nCsA-siRNA NFKBIZ When n is 2, the nCsA-siRNA NFKBIZ The sense chain sequence and antisense chain sequence of the siRNA targeting human NFKBIZ are shown in SEQ ID NO.11 and SEQ ID NO.12, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse NFKBIZ are shown in SEQ ID NO.17 and SEQ ID NO.18; When the nCsA-siRNA NFKBIZ When n is 3, the nCsA-siRNA NFKBIZ The sense chain sequence and antisense chain sequence of the siRNA targeting human NFKBIZ are shown in SEQ ID NO.13 and SEQ ID NO.14, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse NFKBIZ are shown in SEQ ID NO.19 and SEQ ID NO.20; The CsA3-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.7, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.8; The 3CsA-siRNA IL-17 The sense chain sequence and antisense chain sequence of the siRNA targeting human IL-17 are shown in SEQ ID NO.23 and SEQ ID NO.24, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse IL-17 are shown in SEQ ID NO.31 and SEQ ID NO.32; The 3CsA-siRNA IL-1β The sense chain sequence and antisense chain sequence of the siRNA targeting human IL-1β are shown in SEQ ID NO.25 and SEQ ID NO.26, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse IL-1β are shown in SEQ ID NO.33 and SEQ ID NO.34; The 3CsA-siRNA IL-23 The sense chain sequence and antisense chain sequence of the siRNA targeting human IL-23 are shown in SEQ ID NO.27 and SEQ ID NO.28, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse IL-23 are shown in SEQ ID NO.35 and SEQ ID NO.36; The 3CsA-siRNA TNF-α The sense chain sequence and antisense chain sequence of the siRNA targeting human TNF-α are shown in SEQ ID NO.29 and SEQ ID NO.30, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse TNF-α are shown in SEQ ID NO.37 and SEQ ID NO.38; The 3CsA-siRNA NLRP3 The sense chain sequence and antisense chain sequence of the siRNA targeting human NLRP3 are shown in SEQ ID NO.39 and SEQ ID NO.40, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse NLRP3 are shown in SEQ ID NO.45 and SEQ ID NO.46; The 3CsA-siRNA JAK1 The sense chain sequence and antisense chain sequence of the siRNA targeting human JAK1 are shown in SEQ ID NO.41 and SEQ ID NO.42, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse JAK1 are shown in SEQ ID NO.47 and SEQ ID NO.48; The 3CsA-siRNA PDE4 The sense chain sequence and antisense chain sequence of the siRNA targeting human PDE4 are shown in SEQ ID NO.43 and SEQ ID NO.44, and the sense chain sequence and antisense chain sequence of the siRNA targeting mouse PDE4 are shown in SEQ ID NO.49 and SEQ ID NO.50; The 3CsA-ASO IL-17 The ASO sequence targeting human IL-17 is shown in SEQ ID NO.51, and the ASO sequence targeting mouse IL-17 is shown in SEQ ID NO.55; The 3CsA-ASO IL-1β The ASO sequence targeting human IL-1β is shown in SEQ ID NO.52, and the ASO sequence targeting mouse IL-1β is shown in SEQ ID NO.56; The 3CsA-ASO IL-23 The ASO sequence targeting human IL-23 is shown in SEQ ID NO.53, and the ASO sequence targeting mouse IL-23 is shown in SEQ ID NO.57; The 3CsA-ASO TNF-α The ASO sequence targeting human TNF-α is shown in SEQ ID NO.54, and the ASO sequence targeting mouse TNF-α is shown in SEQ ID NO.58; The 20CsA-ASO NLRP3 The ASO sequence targeting human NLRP3 is shown in SEQ ID NO.59, and the ASO sequence targeting mouse NLRP3 is shown in SEQ ID NO.62; The 20CsA-ASO JAK1 The ASO sequence targeting human JAK1 is shown in SEQ ID NO.60, and the ASO sequence targeting mouse JAK1 is shown in SEQ ID NO.63; The 20CsA-ASO PDE4 The ASO sequence targeting human JAK1 is shown in SEQ ID NO.61, and the ASO sequence targeting mouse JAK1 is shown in SEQ ID NO.64; The 10RAP-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.65, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.66; The 10TA-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.67, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.68; The 10Cal-ASO NFKBIZ The ASO sequence targeting human NFKBIZ is shown in SEQ ID NO.69, and the ASO sequence targeting mouse NFKBIZ is shown in SEQ ID NO.
70.
2. The small molecule drug-oligonucleotide conjugate according to claim 1, characterized in that: The small molecule drug and the functional oligonucleotide molecule are covalently coupled via a chemical linker.
3. The small molecule drug-oligonucleotide conjugate according to claim 1, characterized in that: The functional oligonucleotide molecule is one or more of a single-stranded antisense oligonucleotide ASO targeting inflammation-related genes and a small interfering nucleic acid siRNA targeting inflammation-related genes.
4. The small molecule drug-oligonucleotide conjugate according to claim 3, characterized in that: When the functional oligonucleotide molecule is siRNA, the small molecule drug is covalently coupled to the 3' end of the positive strand of the siRNA; when the functional oligonucleotide molecule is ASO, the small molecule drug is covalently coupled to the 3' end or 5' end of ASO.
5. Use of the small molecule drug-oligonucleotide conjugate according to any one of claims 1 to 4 in the preparation of a drug for treating inflammation-related diseases; the inflammation-related diseases are dry eye disease and psoriasis.
